Patent Grant
8770199
This application claims, under 35 USC §119(e), the benefit of U.S. Provisional Application No. 61/733,134, filed Dec. 4, 2012, U.S. Provisional Application No. 61/784,238, filed Mar. 14, 2013, and U.S. Provisional Application No. 61/856,367, filed Jul. 19, 2013, the contents of each of which are hereby incorporated by reference in their entireties.
The present invention generally relates to improving the accuracy and/or precision of nitric oxide therapy, reducing the dilution of inhaled nitric oxide, and/or ensuring mixing within the patient's nose.
Nitric oxide (NO) gas, when inhaled, dilates blood vessels in the lungs, improving oxygenation of the blood and reducing pulmonary hypertension. Because of this, some provide nitric oxide as a therapeutic gas in the inspiratory breathing gases for patients with pulmonary hypertension.
Typically, inhaled NO is delivered in a carrier gas from a high pressure source (e.g., a pressurized cylinder) to the patient at, or near, ambient pressure by means of a respiratory tube for ICU ventilator bound/dependent or anesthesia patients or a nasal cannula for spontaneously breathing patients. Delivering an accurate and consistent dose to the patient through a nasal cannula can be particularly challenging when the flow rate is pulsatile, for example, because dilution of the dose can occur.
Accordingly, a need exists for new methods and apparatuses for preventing dilution of dosing within the delivery conduit of a nitric oxide delivery apparatus, as well as methods of manufacturing such apparatuses.
Aspects of the present invention relate to improved nasal cannulas that minimize retrograde flow and/or permeation of oxygen, air, and/or other gases during NO therapy while allowing NO delivery to one or both nares of the nostril. Such cannulas can reduce dilution of the delivered dose by using cannula materials and/or coatings that limit oxygen diffusion through the cannula walls and/or utilize cannula configurations that prevent mixing of co-delivered O2 and NO and/or reduce retrograde flow through the patient end of the cannula.
Aspects of the present invention also relate to methods of minimizing the dilution of the NO dose. Other aspects of the present invention pertain to methods of treatment utilizing these nasal cannulas and/or methods of administration. Other aspects of the present invention relate to methods of manufacturing multi-lumen cannulas and their nosepieces.
In exemplary embodiments, a nasal cannula of the present invention can be for delivering at least one therapeutic gas to a patient in need thereof. The nasal cannula can include a first lumen, a second lumen, and a third lumen. The nasal cannula can also include a cannula nosepiece. The first lumen can be capable of delivering a first therapeutic gas to a patient in need thereof, the second lumen can be capable of transmitting a pressure change to a pressure change sensor and/or breath sensor, the third lumen can be capable of delivering a second therapeutic gas to the patient, and/or the cannula nosepiece can include separate flow paths to the patient for the first lumen, the second lumen, and the third lumen. The at least one therapeutic gas can be nitric oxide.
In exemplary embodiments, a nasal cannula of the present invention can be used for therapeutic gas delivered to a patient. The nasal cannula can include a first lumen, a second lumen, and/or a third lumen. The first lumen can be a first therapeutic gas lumen for delivering a first therapeutic gas to a patient, the second lumen can be a triggering lumen, and the third lumen can be a second therapeutic gas lumen for delivering a second therapeutic gas to the patient. Further, a cannula nosepiece can allow separate flow paths to the patient for the first therapeutic gas lumen, the triggering lumen, and/or the second therapeutic gas lumen.
In exemplary embodiments, the nasal cannula can reduce dilution of one or more of the first and second therapeutic gases delivered to the patient and/or can be configured to be placed in fluid communication with at least one system to deliver the first and/or second therapeutic gases to the patient. The nasal cannula can inhibit mixing of nitric oxide and oxygen and/or the nasal cannula can reduce delivery of nitrogen dioxide to the patient.
In exemplary embodiments, one or more of the first and second therapeutic gases to the patient for treatment of pulmonary hypertension. In exemplary embodiments, the nasal cannula can deliver the first and/or second therapeutic gases to the patient for treatment of pulmonary hypertension, pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD), pulmonary hypertension as pulmonary arterial hypertension (PAH), pulmonary hypertension secondary to idiopathic pulmonary fibrosis (IPF), and/or pulmonary hypertension secondary to sarcoidosis. The first therapeutic gas and the second therapeutic gas can be different gases or the same gas. In exemplary embodiments, the first therapeutic gas can be nitric oxide and the second therapeutic gas can be oxygen and/or the first therapeutic gas lumen for delivering nitric oxide can be smaller than the second therapeutic gas lumen for delivering oxygen and/or the triggering lumen. In exemplary embodiments, the first therapeutic gas lumen can be for delivering nitric oxide and/or can be about six feet to about eight feet in length having an inner diameter of about 0.01 inches to about 0.10 inches. In exemplary embodiments, the triggering lumen can be about six feet to about eight feet in length having an inner diameter of about 0.05 inches to about 0.20 inches.
In exemplary embodiments, the first therapeutic gas can be nitric oxide and/or the cannula nosepiece can include a nitric oxide flow path that can have an inner diameter that may be smaller than an inner diameter of the first therapeutic gas lumen. In exemplary embodiments, the first therapeutic gas can be nitric oxide and/or the cannula nosepiece can include a nitric oxide flow path having a volume that may be less than about 10% of a minimum pulse volume of the pulse of nitric oxide. The cannula can include a wall material having a low oxygen transmission rate that can be between
In exemplary embodiments, the cannula can further include a fourth lumen that can be another first therapeutic gas lumen for delivering the first therapeutic gas to the patient. Further, the first lumen can deliver the first therapeutic gas to one nostril of the patient and the fourth lumen can deliver the first therapeutic gas to another nostril of the patient. In exemplary embodiments, the cannula can include at least one check valve in fluid communication with the first therapeutic gas lumen, a cannula key, a scavenging material, and/or a flexible support bridge that cushions the patient's nasal septum.
In exemplar embodiments, a nasal cannula of the present invention can be used for therapeutic gas delivered to a patient. The nasal cannula can include a first lumen, a second lumen, and a third lumen. The first lumen can be a first therapeutic gas lumen for delivering a first therapeutic gas to a patient, the second lumen can be a triggering lumen, and/or the third lumen can be a second therapeutic gas lumen for delivering a second therapeutic gas to the patient. The first therapeutic gas lumen, the triggering lumen, and the second therapeutic gas lumen can aggregate at a cannula nosepiece. The cannula nosepiece can allow separate flow paths to the patient for the first therapeutic gas lumen, the triggering lumen, and/or the second therapeutic gas lumen. The first therapeutic gas lumen can have an inner diameter that can be smaller than an inner diameter of the second therapeutic gas lumen and an inner diameter of the triggering lumen and/or the first therapeutic gas lumen can have an inner diameter that can larger than an inner diameter of the flow path for the first therapeutic gas lumen at the cannula nosepiece.
In exemplary embodiments, the nasal cannula can reduce dilution of the first and/or second therapeutic gases delivered to the patient and/or can be configured to be placed in fluid communication with at least one system to deliver the first and/or second therapeutic gases to the patient. The nasal cannula can inhibit mixing of nitric oxide and oxygen and/or the nasal cannula can reduce delivery of nitrogen dioxide to the patient.
In exemplary embodiments, one or more of the first and second therapeutic gases to the patient for treatment of pulmonary hypertension. In exemplary embodiments, the nasal cannula can deliver the first and/or second therapeutic gases to the patient for treatment of pulmonary hypertension, pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD), pulmonary hypertension as pulmonary arterial hypertension (PAH), pulmonary hypertension secondary to idiopathic pulmonary fibrosis (IPF), and/or pulmonary hypertension secondary to sarcoidosis. In exemplary embodiments, the first therapeutic gas lumen can be for delivering nitric oxide and can be about six feet to about eight feet in length having an inner diameter of about 0.01 inches to about 0.10 inches. The triggering lumen can be about six feet to about eight feet in length having an inner diameter of about 0.05 inches to about 0.20 inches.
In exemplary embodiments, the first therapeutic gas can be nitric oxide and the cannula nosepiece can include a nitric oxide flow path having a volume that can be less than about 10% of a minimum pulse volume of the pulse of nitric oxide. The cannula can include a wall material having a low oxygen transmission rate that can be between
In exemplary embodiments, the cannula can include at least one check valve in fluid communication with the first therapeutic gas lumen, a cannula key, a scavenging material, and/or a flexible support bridge that cushions the patient's nasal septum.
In exemplar embodiments, a nasal cannula of the present invention can be used for therapeutic gas delivered to a patient. The nasal cannula can include a first lumen, a second lumen, and a third lumen. The first lumen can be a first therapeutic gas lumen for delivering nitric oxide gas to a patient, the second lumen can be a triggering lumen, and the third lumen can be a second therapeutic gas lumen for delivering one or more of oxygen gas and air gas to the patient. The first therapeutic gas lumen, the triggering lumen, and/or the second therapeutic gas lumen can aggregate at a cannula nosepiece, the cannula nosepiece can allow separate flow paths to the patient for the first therapeutic gas lumen, the triggering lumen, and/or the second therapeutic gas lumen. The flow path for the first therapeutic gas lumen for delivering nitric oxide to the patient can have a volume at the cannula nosepiece that can be less than about 10% of a minimum pulse volume of the pulse of nitric oxide. The first therapeutic gas lumen can have an inner diameter that can be smaller than an inner diameter of the second therapeutic gas lumen and an inner diameter of the triggering lumen and/or the first therapeutic gas lumen can have an inner diameter that can be larger than an inner diameter of the flow path for the first therapeutic gas lumen at the cannula nosepiece.
In exemplar embodiments, a method for treating pulmonary hypertension can include administering nitric oxide gas to a patient in need thereof, wherein the nitric oxide can be administered through a nasal cannula, wherein the nasal cannula can include a first lumen, a second lumen, and a third lumen. In exemplary embodiments, nitric oxide is for treatment of pulmonary hypertension. In exemplary embodiments, the nasal cannula can deliver nitric oxide to the patient for treatment of pulmonary hypertension, pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD), pulmonary hypertension as pulmonary arterial hypertension (PAH), pulmonary hypertension secondary to idiopathic pulmonary fibrosis (IPF), and/or pulmonary hypertension secondary to sarcoidosis.
In exemplar embodiments, the nitric oxide can be pulsed early in inspiration and/or delivered in the first half of inspiration. In exemplar embodiments, the nitric oxide can be administered by pulsed inhalation to spontaneously breathing patients, the nitric oxide can be administered at the onset of inspiration, the dose of nitric oxide can be about 0.010 mg/kg/hr, and/or the dose can be administered at the onset of inspiration over a pulse width of less than 260 milliseconds. In exemplar embodiments, the method can further comprise administering oxygen to the patient.
In exemplar embodiments, a method of administering nitric oxide of the present invention can be used for treating pulmonary hypertension. The method can include administering nitric oxide gas to a patient, wherein nitric oxide can be administered through a nasal cannula. The nasal cannula can include a first lumen, a second lumen, and a third lumen. The first lumen can be a first therapeutic gas lumen for delivering a nitric oxide gas to a patient, the second lumen can be a triggering lumen, and the third lumen can be a second therapeutic gas lumen for delivering oxygen gas to the patient. Further, a cannula nosepiece can allow separate flow paths to the patient for the first therapeutic gas lumen, the triggering lumen, and/or the second therapeutic gas lumen. The second lumen can be for sensing the onset of inspiration and/or a change in pressure.
In exemplary embodiments, the nasal cannula can reduce dilution of one or more of the first and second therapeutic gases delivered to the patient and/or can be configured to be placed in fluid communication with at least one system to deliver the first and/or second therapeutic gases to the patient. The first therapeutic gas lumen for delivering nitric oxide can be smaller than both of the second therapeutic gas lumen for delivering oxygen and the triggering lumen. The first therapeutic gas lumen can have an inner diameter dimension that can be selected to be substantially small to reduce nitric oxide dilution by reducing transit time of NO through the cannula while also being substantially large enough to not cause significant backpressure and not substantially distort nitric oxide pulses and/or the triggering lumen can have an inner diameter dimension that can be selected to be substantially small while also can be substantially large enough to reduce delay and distortion of pressure signals. The cannula nosepiece can include a nitric oxide flow path that can have an inner diameter that can be smaller than an inner diameter dimension of the first therapeutic gas lumen.
In exemplary embodiments, the cannula can include at least one check valve in fluid communication with the first therapeutic gas lumen, a cannula key, a scavenging material, and/or a flexible support bridge that cushions the patient's nasal septum. The cannula can include a wall material having a low oxygen transmission rate that can be between
In exemplary embodiments, the cannula can further include a fourth lumen that can be another first therapeutic gas lumen for delivering the first therapeutic gas to the patient. Further, the first lumen can deliver the first therapeutic gas to one nostril of the patient and the fourth lumen can deliver the first therapeutic gas to another nostril of the patient.
The features and advantages of various embodiments of the present invention will be more fully understood with reference to the following, detailed description when taken in conjunction with the accompanying figures, wherein:
The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled therapeutic gases such as nitric oxide (NO) and/or limiting mixing of the inhaled therapeutic gases prior to delivery into the patient's nose. As described herein, NO dilution can occur because of various factors such as, but not limited to, NO mixing with oxygen and/or air. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed. For example, the various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. of the present invention can reduce mixing of NO with oxygen and/or air (e.g., prior to being delivered into the patient's nose, etc.) thereby reducing dilution of intended NO doses.
Due to the unique nature of NO delivery, many factors need to be considered to ensure accurate and precise delivery of doses of NO to the patient. Unlike the administration of other gases, such as oxygen (O2), NO dosing can be particularly susceptible to dilution because, amongst other things, the dose volume may be less than 1 ml (e.g. a substantially small dose that can be lost to ambient) and/or NO can be reactive with O2 present in ambient air and/or co-administered O2 producing nitrogen dioxide (NO2). Further, the timing of NO delivery can also be more critical (e.g., for efficacy) than the timing of other gases (e.g., O2 delivery), so a need exists to reduce NO dilution and ensure that the beginning of a patient's breath can be accurately determined as soon as possible and/or to ensure that the NO dose waveform does not significantly distort while traveling through the nasal cannula from the NO delivery device to the patient. Further, patient comfort may need to be factored into the design of the nasal cannula, for example, because the nasal cannula may be used for prolonged periods of time.
Various cannulas, systems, and methods of the present invention can use, modify, and/or be affiliated with various systems for delivering pharmaceutical gas to a patient and/or for delivering a pulse of pharmaceutical gas to a patient. For example, the various cannulas, systems, and methods of the present invention can use, modify, and/or be affiliated with at least the therapeutic gas delivery systems illustratively depicted in
Referring to
Delivery of the NO/N2 gas mixture (at times referred to simply as nitric oxide, NO, etc.) to the patient typically requires that the NO gas travel from a high pressure NO source (e.g., a pressurized cylinder, pressurized cylinder affiliated with NO delivery device 103, etc.) to the patient at, or near, ambient pressure, for example, via a delivery tube for ICU ventilator bound/dependent and/or anesthesia patients and/or via a nasal cannula for spontaneously breathing patients. It will be understood that various techniques and/or embodiments of the invention disclosed herein can be used for a delivery tube and/or a nasal cannula as well as other like apparatuses such as nasal pillows and/or nasal masks, to name a few. For ease, at times only a cannula is shown and/or described. This is merely for ease and is in no way meant to be a limitation.
This above described transit of the NO, ideally, will be devoid of contact with other gasses, such as ambient air, oxygen, carbon dioxide, etc., until the gas enters the patient's upper respiratory tract. However, in practice, this may not be easily achieved. By way of example, oxygen and/or ambient air can enter delivery system 100 at a number of points such as, but not limited to:
The dilution of NO during pulsed NO therapy can be problematic because only a substantially small volume of NO may be delivered to the patient. For example, the NO-containing gas can be administered in pulses that may be less than one (1) milliliter (ml). With substantially small pulse volumes, even small volumes of retrograde flow and/or diffused gases can be significant, for example, because the small NO dose may be easily diluted. Of course larger volumes of NO can also be diluted.
Minimization of NO/O2 Contact Due to O2 Diffusion:
Minimization of NO Transit Time
One or more embodiments of the present invention relate to nasal cannulas that address sources of NO/O2 contact (e.g., one or more of the above sources of NO/O2 contact) and thereby dilution (e.g., by mixing of NO with O2, etc.) of the intended NO dose by minimizing NO contact time with O2, via minimizing transit time through the cannula, minimizing the transit of oxygen across the cannula walls, and/or minimizing the amount of O2 coming in contact with NO. Referring to
Small ID NO Lumen
In one or more embodiments, cannulas can be provided that include a smaller inside diameter (ID) delivery tube/lumen for NO to, for example, reduce dilution of the intended NO doses. This smaller ID tube can reduce the transit time of the NO molecules through the cannula. This in turn can reduce the time available for mixing with oxygen which can be diffusing across the walls of the cannula and oxidizing the internal NO into NO2.
By way of example, to reduce dilution of intended NO doses by minimizing NO transit time through the cannula, the ID for delivery tube/lumen for NO can be about 0.01 inches to about 0.10 inches and/or about 0.03 inches to about 0.08 inches. In exemplary embodiments, the ID of the delivery tube/lumen for NO can be selected to ensure reduced transit time of NO (e.g., reducing NO dilution, etc.) while not resulting in significant backpressure and/or NO pulse shape distortion and/or NO waveform distortion (discussed below in greater detail). To reduce transit time as well as not significantly cause backpressure and/or distortion, the ID for delivery tube/lumen for NO may not be substantially smaller than about 0.03 inches, for example, for a cannula having a length of about 6 feet to 8 feet. For shorter lengths a smaller ID may be used and/or for longer lengths a larger ID may be used as resistance and/or distortion can be a function of both tube ID and tube length.
In exemplary embodiments, the ID of shorter tubes/lumens for NO delivery (e.g. such as the cannula nares, shorter nasal cannulas, etc.) can have a substantially smaller tube ID than for delivery tubes/lumen for NO, which may also have a substantially small ID as described above, without significant backpressure and/or NO pulse shape and/or waveform distortion occurring.
In exemplary embodiments, the potential for time of exposure of NO to O2 can be minimized using other techniques such as, but not limited to, increasing the velocity of delivery of NO through the NO lumen. The velocity of NO through the NO lumen can be increased by, for example, increasing the pressure gradient within the system and/or by reducing the diameter of the tube. Although the NO velocity can be increased to reduce the exposure time of NO to O2, the velocity can be required to be minimized so that the pulse shape is not substantially distorted, the patient does not experience discomfort, and/or by factoring in any other competing metric.
It will be understood that the any of above teachings (e.g., small ID for the delivery tube lumen for NO, etc.) can be combined with any of the other pneumatic configurations, cannula configurations, and/or teachings and/or embodiments described herein. For example, the above teachings (e.g., small ID for the delivery tube/lumen for NO, etc.) can be used with the below described mono-lumen cannulas, dual-lumen cannulas, tri-lumen cannulas, quad-lumen cannulas, and/or any other teachings and/or embodiments described herein.
Materials to Limit Oxygen Diffusion and/or Remove O2 and/or NO2
Currently, many use polyvinyl chloride (PVC) and/or silicone as a common material for constructing nasal cannulas; however, oxygen can diffuse through the lumen walls of these nasal cannulas. To minimize the oxygen contact occurring due to oxygen diffusion, permeation, and/or transmission across the cannula's walls, cannula wall materials can be selected that minimize the oxygen diffusion rate, permeability rate, and/or oxygen transmission rate (OTR). In exemplary embodiments, the cannula wall can include a material with a low oxygen diffusion coefficient, permeability rating, and/or oxygen transmission rate (OTR). By way of example, the cannula wall can include a material that can have an oxygen transmission rate (OTR) from about 0.001 to about 10, for example, using the following units:
where:
At times, when describing oxygen diffusion, permeation, and/or transmission across the cannula's walls and/or cannula's materials, reference may only be made to at least one of diffusion rates, diffusion coefficients, permeability rates, permeability ratings, and/or OTR. It will be understood that reference to any of the above terms, when applicable, can be used with and/or replaced by any of the above terms, and the like. For ease, at times only one and/or some of the above terms are described. This is merely for ease and is in no way meant to be a limitation.
In exemplary embodiments, cannula materials (e.g., material for the cannula tubing, the cannula nosepiece, etc.) can be adjusted and/or varied to address O2 permeation along with patient comfort.
In exemplary embodiments, cannulas can be constructed using polyurethane and/or similar soft material. In exemplary embodiments, the polyurethane and/or similar soft material can include an additive to enhance the resistance to oxygen diffusion and/or tube coaxially located about at least some of the cannula for NO delivery filled with a gas providing resistance to oxygen diffusion. The cannulas can be constructed by coaxially coating a tube and/or co-extruding two or more materials (e.g., to form the tube, etc.). Of course other methods and/or techniques for construction are within the scope of the disclosure.
Examples of at least some materials which can be used for construction and/or that can have desired oxygen permeation properties include, but are not limited to, polymers such as polyvinylidene chloride (PVDC), ethylene vinyl alcohol (EVOH), polyamide (PA), polyvinylidene difluoride (PVDF), fluorinated polyurethane, Nylon 6, Nylon 12, and/or similar materials, to name a few. Further, PVC can be used as the cannula material with one or more materials and/or additives, such as oxygen resistant polymers, incorporated to reduce the oxygen permeation, diffusion coefficient, and the like. Oxygen resistant polymers can be incorporated with the polyurethane, PVC, and/or other cannula materials, for example, through co-extrusion. By way of example, such an extrusion can be achieved with co-extrusion dies and/or using other known techniques.
Tubing/lumen barriers to oxygen ingress can take one of a number of potential forms such as, but not limited to:
Homogenous and/or Single Material Extrusions with Low Oxygen Permeability:
In exemplary embodiments, materials such as polyvinylidine chloride (PVDC, trade name Saran®), ethylene vinyl alcohol (EVOH), Nylon 6, Nylon 12, and/or any homogenous and/or single material extrusions with low oxygen permeability can be used for the cannula material. Other materials are envisioned with these properties and the use of substitute low oxygen permeation extrusion compatible material is within the scope of this invention.
Co-Extrusions of Two or More Polymers:
In exemplary embodiments, a tube-in-tube and/or multilayered sandwich configurations can be constructed using co-extrusions of two or more polymers. For example, two or more polymers, with at least one having low oxygen permeation properties, can be co-extruded (e.g., using common co-extrusion methods known in the art) to construct a tube-in-tube or multilayered sandwich configuration. The low oxygen permeation layer can include the polymers disclosed herein (e.g., such as those listed in the previous section) and/or other polymers with similar characteristics. Since these polymers may or may not co-extrude well with other polymers, it may be necessary to extrude an intermediate or so called tie-layer polymer. Exemplary co-extruded polymers can include, but are not limited to, PVC/EVOH/PVDC, PVC/EVOH/PFDF, fluorinated polyurethane/EVOH/PVDC and fluorinated polyurethane/EVOH/PVDF, PVC/PVDC, Polyurethane/PVDC, PVC/Nylon 6, PVC/Nylon 12, PVC/PVDC/Nylon 6, PVC/PVDC/Nylon 12, Polyurethane/PVDC/Nylon 6, Polyurethane/PVDC/Nylon12, tie layer polymers, any combination and/or separation thereof, and/or any other material that can be used with co-extrusions of two or more polymers.
In exemplary embodiments, co-extrusions can be layered in a specific order, for example, to reduce oxygen permeation and/or diffusion and/or for construction purposes. For example, if an adhesive used (e.g., in the joining of components of the cannula, etc.) bonds PVC to PVC then the outer layer of a co-extrusion exposed to such adhesive can be PVC. Further, additional polymers (e.g., which may have reduced properties when in contact with water vapor) such as, but not limited to, EVOH can be sandwiched inside hydrophobic and/or water resistant outer and/or inner extrusion layers to minimize the contact of the internal compound with water vapor.
Surface Treatment/Surface Coatings Over Tubing:
In exemplary embodiments, surface coatings (e.g., surface treatments, surface coatings, etc.) for low oxygen permeation can be applied to nasal cannula construction. Such coatings can include, but are not limited to, vacuum deposited silicon dioxide (silica) and/or aluminum (e.g., oxides of aluminum, etc.) coatings heated above their sublimation temperature that can be deposited in thin layers a few microns (or less) thick. For example, silica coatings can be about 0.001 microns to about 10 microns and/or about 0.01 microns to about 1 micron, and/or about 0.04 microns.
In exemplary embodiments, silica coatings can be deposited on plastic in layers that can be substantially thin enough such that flexibility of the plastic may not be materially affected. It will be understood that any reasonable technique can be used for deposition of such materials. For example, low cost deposition can be achieved using chemical vapor deposition treatment. Of course other deposition methods for these coatings can also be used such as, but not limited to, E-beam and Thermal Evaporation, DC Magnetron Sputtering, Plasma-Assisted Reactive Sputtering, any combination and/or further separation thereof, and/or any technique capable of deposition.
In exemplary embodiments, other coatings such as, but not limited to, thermoset epoxy-amine coatings, epoxy-amine coatings, etc. can be used. Coatings can be applied and/or provided using techniques described herein and/or known techniques.
Blends:
In exemplary embodiments, materials can be blended together to obtain the beneficial properties of one or the other materials and/or used as the cannula material. In exemplary embodiments, Nylon 6 and EVOH, which can adhere to each other in co-extrusions without the need for a tie layer, can be used as a blended cannula material. Other blends can include, but are not limited to, Nylon 6 with amorphous nylon and Nylon 6 with HDPE. Of course other blends can be used.
In exemplary embodiments, a later material can be coated over an earlier material. By way of example, when two materials are not compatible with co-extrusion due to different melt temperatures, one polymer can be extruded first and the second polymer can be heated and coated over the first in a secondary operation.
Scavengers/Getters:
In exemplary embodiments, scavengers can be coated to the inside of the lumen (e.g., by baking off the liquid in a liquid suspension of the scavenger to the inside of the lumen, by condensing out the scavenger on the inside of the lumen by evaporative processes, by absorbing/adsorbing to the inside surface of the lumen using a liquid or gaseous scavenger source, by chemically bonding the scavenger to the inside surface of the cannula, etc.) and/or the scavenger can be packaged within the device connector and/or nosepiece, for example, as a plug (e.g., a plug with at least one hole to allow flow of gas through it, etc.) to scavenge oxygen and/or nitrogen dioxide. Such scavengers can include, but are not limited to, compounds such as activated alumina, ascorbic acid, and/or any other scavenging compound. Potential drawbacks of such an approach include the finite lifespan of the scavenging material. This drawback can be overcome by factoring in use duration of the cannula into the design. At least one additional potential drawback can be that any plug configuration for gas transit through a scavenger may distort the gas waveform. In light of this plugs described may be designed to minimize such waveform distortion. Any method can be used to coat the inside of the lumen. By of example, a liquid that is concentrated with a scavenger (e.g., ascorbic acid) can be passed through the tube and then dried on such that it may then be deposited on the inner wall of the tube.
In exemplary embodiments, activated alumina can be used in the cannula, for example, as a coating in the inside of the lumen, as a plug fitting, and/or used in any other way, for example, for the capture of nitrogen dioxide. With a thin layer of alumina coated to the inside of the lumen, the effect can not only be a reduction of the oxygen permeation rate, but can also be successful for capture of nitrogen dioxide. Activated alumina and/or other scavengers can also be made in the form of a plug fitted into the tube, for example, in an area close in proximity to the nostrils of the patient. The plug may be designed to minimize pressure drop and/or to maintain the shape of nitric oxide pulse wave. The high surface area of activated alumina can effectively scrub nitrogen dioxide from the gas mixture. Further, the scavenger can also be located in the device, for example, at the device connector. In this fashion, the scavenger can be part of the cannula and/or may be removable (e.g., such that it may be removed when changing the cannula) and/or the design life of the scavenger can be matched to anticipated and/or actual use duration of the cannula.
It will be understood that the invention is not limited to activated alumina and that any material with a high surface area, substantial nitrogen dioxide scrubbing capability, proper pore sizes, enough physical strength so that the shape could be maintained, and/or that may not generate powders and/or other materials that may shed or decouple from the cannula can act in the capacity of the scrubbing material. It is further understood that internal filtering may be used to contain shedding compounds to prevent aspiration in the respiratory system. Examples of scrubbing materials include, but are not limited to, zeolites, silica-alumina, activated carbon/coal, and adsorbents that can have solid base sites on the surface. For ease, at times, activated alumina is described as a scrubbing material. This is merely for ease and is in no way meant to be a limitation.
In exemplary embodiments, a reducing agent can be coated on the surface of the scrubbing material, for example, to enhance its ability to capture and/or reduce nitrogen dioxide to nitric oxide. Such reducing agents include, but are not limited to, ascorbic acid.
In exemplary embodiments, additives can be added to the polymer to change the permeation/barrier properties such as, but not limited to, oxidizable plastic (e.g. PET or polyamide), nanoclays, any combination and/or further separation thereof, and/or any other additive. Additives can work to scavenge the oxygen and/or provide a barrier to permeation within the polymer matrix, either of which can result in reduced oxygen permeating through the material. Oxidizable plastics (e.g. PET or polyamide) can react with the oxygen that may be permeating through the polymer matrix. Oxygen that may be permeating through the membrane can react with the oxidizable plastic prior to getting through the cannula and/or reacting with NO. Nanoclays (e.g., that may tend to have a plate like morphology) can provide a barrier to permeation, for example, when adequately dispersed within the polymer matrix. When dispersed, diffusion can be required to occur around the plates, which can result in a tortuous path through the polymer thereby effectively reducing the gas permeability.
It will be understood that the any of above teachings (e.g., materials, etc.) can be combined with any of the other pneumatic configurations, cannula configurations, and/or teachings and/or embodiments described herein. For example, the above teachings (e.g., materials, etc.) can be used with the below described mono-lumen cannulas, dual lumen cannulas, tri-lumen cannulas, quad lumen cannulas, and/or any other teachings and/or embodiments described herein.
Configurations
Retrograde Flow
Referring to
As shown in
Noting the above, the amount of dilution resulting from retrograde flow can be dependent on the volume of the lumen associated with NO delivery (e.g., the NO lumen; combined NO and triggering lumen; combined NO, triggering, and O2/air lumen; etc.) at the cannula nosepiece (e.g., flow path) where retrograde flow may occur. The segment where retrograde flow may occur can have any shape. For ease, this segment where retrograde flow occurs is, at times, described as being “U” shaped, and the like. This is merely for ease and is in no way meant to be a limitation.
In exemplary embodiments, optimized ID dimensions (e.g., ID size, ID shape, etc.) of the lumen associated with NO delivery (e.g., the NO lumen; combined NO and triggering lumen; combined NO, triggering, and O2/air lumen; etc.) at the nosepiece (e.g., flow path) can be selected to reduce the volume of the “U” shaped region thereby minimizing the potential volumetric exchange associated with retrograde flow and/or dilution resulting from retrograde flow. Further, in exemplary embodiments, such optimal ID dimensions can vary depending on the volume of NO gas delivered. By way of example, a nitric oxide delivery device can deliver pulses of NO-containing gas with a minimum dose volume of 0.35 ml. In order to ensure volumetric dosing accuracy, it may be preferable that no more than a small percentage (e.g., 10%, 5%, 20%, etc.) of the dose can be lost due to retrograde flow.
One or more embodiments of the present invention limits the internal volume of this “U” shape to be no more than a small percentage (e.g., 10%, 5%, 20%, etc.) of the minimum dose volume (e.g., 0.035 ml for a 0.35 ml pulse of therapeutic gas) to ensure that if NO loss occurs it is an acceptable amount of NO loss due to retrograde flow (e.g., loss to ambient during the exhalation phase). Following the above example, for a 10% minimum dose volume of 0.035 ml, the lumen ID within the “U” segment may be no more than 0.046 inches given a prong length of 0.315 inches and a prong spacing of 0.63 inches. Therefore, a lumen ID significantly larger than 0.046 inches may not be advantageous to maintaining dose volume accuracy for minimum dose volumes of 0.35 ml.
It will be understood that the mathematics of this construct can be modified by variations in systems such as, but not limited to, systems with larger or smaller minimum dose volumes appropriately, systems with different prong lengths, and/or systems prong spacing, to name a few. One skilled in the art can perform the required calculations to determine the ID required to provide a desired volume in the “U” shaped segment so that it does not exceed 10% of the dose volume. Furthermore, depending on the required accuracy for the dosing, the internal “U” volume or other volume available for cross-flow can be, but is not limited to, less than 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the dose volume, to name a few.
For example, if the “U” shape consists of two nares and a backplane, the maximum dimensions such that the “U” volume does not exceed 20% of the minimum dose volume can be calculated using the following formula, wherein backplane refers to the length of the lumena inside the nosepiece and/or which forms the base of the “U” shape:
Minimum Dose Volume>5[2π(Prong Diameter/2)2*(Prong Length)+π(Backplane Diameter/2)2*(Backplane Length)]
Thus, if the minimum dose is known, the dimensions of the cannula “U” section can be calculated. For dosing accuracies other than 20%, the volume ratio factor of 5 can be changed accordingly with the volume ratio factor being equal to [100/(dose accuracy %)].
In exemplary embodiments, during exhalation and/or prior to inhalation (e.g., sensed and/or detected by the delivery device, etc.) the U-shaped volume in the nosepiece can be purged with a pulse of NO substantially equal to the U-volume. This can cause the U-volume to be substantially filled with NO (e.g., after exhalation). Further, this NO filling the U-volume can be delivered to the patient during the next inhalation, for example, ensuring early delivery of NO to the patient to provide optimal clinical efficacy (e.g., discussed below).
In exemplary embodiments, retrograde flow can be reduced by at least reducing the ID of the NO delivery lumen within the nasal prong (e.g., NO flow path) so that the resistance to flow through the NO lumen at the nasal prong can be increased. Noting this configuration, under the same pressure differential, the flow within the NO lumen of the nasal prongs can be reduced as compared to prongs with larger lumen. This can result in reduced cross flow under at least these conditions, for example, because the smaller ID NO lumen can produce gas flow resistance which can be inversely proportional to the fourth power of lumen's radius by Poiseuille's Law.
In exemplary embodiments, retrograde flow can be reduced by using valves and/or check valves, for example, as discussed below in greater detail.
At times, the NO lumen described herein may be described as being optimized for a minimum pulse volume of 0.35 ml and/or allowed 10% dosing error resulting in an allowable U-shaped volume in the NO lumen (e.g., of 0.035 ml). In exemplary embodiments, changes in this minimum pulse volume and/or the optimal pulse volume range may impact at least the NO lumen size. For example, should the minimum pulse volume be smaller due to, for example, higher nitric oxide concentrations being used, the inner diameter of the NO lumen and/or “U” volume may be decreased to ensure the 10% error goal. For example, the NO lumen and/or “U” volume may be decreased taking into account the various metrics for optimization such as, but not limited to, pulse shape. Further, for example, should the minimum pulse volume be increased due to, for example, the use of lower concentration nitric oxide, then the inner diameter of the NO lumen and/or “U” volume may be increased. For example, the NO lumen and/or “U” volume may be increased taking into account the various metrics for optimization such as, but not limited to, pulse shape. It will be understood that if the NO lumen and/or “U” volume is too large (e.g., about 0.1 ml to about 0.5 ml) then small volume pulses may not be able to be delivered accurately, delivery may be delayed, dilution may occur, and/or other problems may occur due to the unique nature of NO delivery.
Minimizing Delay and/or Distortion
For nitric oxide delivery systems (e.g., that may pulse nitric oxide gas to patients) to have optimal clinical efficacy it may be necessary to deliver a pulse or flow of nitric oxide to the patient as early in the inspiratory phase as possible and/or with a desired flow waveform (e.g., pulse shape). Noting this, pneumatic delays may be and/or should be minimized because, for example, pressure signals from the patient can be used as an indication of patient inspiratory effort and/or the beginning of patient inspiration. Also, distortion of pulse or flow waveforms may be and/or should be minimized because, for example, waveform shape and/or timing may be tied to clinical efficacy. Accordingly, one or more embodiments of the present invention relate to nasal cannula configurations that minimize the delay and/or distortion of pressure signals, for example, when in transit through the cannula from the patient back to the device and/or that minimize distortion of flow waveforms.
In exemplary embodiments, the lumen of the cannula affiliated with triggering (e.g., the triggering lumen; combined triggering and NO lumen; combined triggering, NO, and O2/air lumen; etc.) can be configured to minimize the delay and/or distortion of pressure signals when in transit through the cannula. To minimize the delay and/or distortion of pressure signals when in transit through the cannula, the cross-section of the lumen affiliated with triggering can be selected to reduce delay and/or distortion and/or the cross-sectional size can be increased and/or maximized to reduce delay and/or distortion.
In exemplary embodiments, the lumen of the cannula affiliated with NO delivery (e.g., NO lumen; combined NO and triggering lumen; combined NO, triggering, and O2/air lumen; etc.) can be configured to minimize distortion of flow waveforms. To minimize distortion of flow waveforms the cross-section of the lumen affiliated with NO delivery can be increased and/or maximized and/or the shape of the cross-section can be selected to reduce delay and/or distortion. Further, in exemplary embodiments, to minimize distortion of flow waveforms the lumen affiliated with NO delivery can be made having reduced compliance, i.e., having increased stiffness. For example, to minimize distortion of flow waveforms the lumen affiliated with NO delivery can be made of a substantially rigid material. The rigidity of the material can be selected for reducing compliance while still factoring in at least patient comfort.
Competing Metrics
In at least some embodiments the cannula can be configured such that one lumen can be for delivering NO and be for triggering (e.g., mono-lumen cannulas, dual-lumen cannulas, etc.). Such configurations can require optimizing the lumen for both NO delivery and for triggering to have minimal dilution of NO doses as well as allow the trigger signal to propagate to the device without attenuation substantially over the spectral band of human breathing (e.g., 0-4 Hz). This can be substantially difficult as these can be competing metrics for optimization. For example, in order to deliver a pulse and/or flow of NO early in the inspiratory phase, reduce pneumatic delays, reduce distortion of flow waveforms, reduce delay and/or distortion of pressure signals, reduce the volume of NO mixing and/or NO oxidation at the nosepiece, and/or address any other desired property (e.g., for a combined NO/triggering lumen) several competing metrics of the lumen ID can be optimized such as, but not limited to:
a. Reduce NO2 formation→Reduce lumen ID;
b. Maintain volumetric NO dosing accuracy→Reduce lumen ID;
c. Reduce NO flow distortion→Increase lumen ID; and
d. Minimize trigger signal attenuation or delay→Increase lumen ID.
In exemplary embodiments, cannulas of the present invention that have combined NO/triggering lumen configurations can require compromise of the optimal geometry (e.g., shape, size, etc.) of the NO/Trigger lumen to, for example, deliver pulses and/or flows of NO early in the inspiratory phase, reduce pneumatic delays, reduce distortion of flow waveforms, reduce delay and/or distortion of pressure signals, reduce the volume of NO mixing at the nosepiece, and/or NO oxidation at the nosepiece. Such compromise may be required for cannulas of the present invention that have combined NO/triggering lumen (e.g., mono-lumen cannulas, dual-lumen cannulas, etc.). However, cannulas configurations of the present invention that have at least three lumens (e.g., tri-lumen cannula, quad-lumen cannula, etc.), as discussed below, can allow for lumens dedicated to both NO delivery and to the trigger signal and can, in at least some instances, allow for a dedicated O2/air delivery lumen. As such, for cannulas of the present invention with dedicated lumens for NO delivery and triggering (e.g., tri lumen cannulas, quad-lumen cannulas, etc.) the optimized NO lumen can be smaller than the optimized trigger lumen since it may be beneficial to have a larger trigger lumen to ensure at least minimal signal attenuation while it may be beneficial to have a smaller NO lumen to reduce at least dilution of NO. As such, cannulas of the present invention having combined NO/triggering lumens (e.g., mono-lumen, dual-lumen cannulas, etc.) and cannulas of the present invention having dedicated NO delivery lumens and dedicated triggering lumens (e.g., tri-lumen cannulas, quad-lumen cannulas etc.) can have different geometries when optimized.
By way of example, in addition to ensuring the accuracy of volumetric dosing (e.g., described above with respect to minimizing dilution resulting from retrograde flow), the ID of combined NO/triggering lumens can be designed to reduce and/or not produce gas flow distortion and/or undue signal propagation delay, for example, from the patient to the device (e.g., described above with respect to minimizing delay and/or distortion of pressure signals). Such distortion and/or delay may occur as pneumatic tubes may behave as first order pneumatic low pass filters and attenuate higher frequency signal components. Modification of the inner diameters can change the band pass characteristics of the filtering effect. However, as noted earlier, the inner diameter (e.g., at the U) can be fixed to a certain maximum ID based on the required dose delivery accuracy of the system.
In light of at least the above, in exemplary embodiments, to minimize the effects of the potentially frequency attenuated pressure signal: (1) the upstream (close to device) diameter of the combined NO/triggering lumen of cannulas of the present invention can be adjusted to widen (e.g., optimize) the band pass characteristics of the cannula and/or (2) triggering of the initiation of pulse delivery of NO (e.g., by the delivery device) may have the typical threshold pressure trigger strategy (e.g., the pressure signal may be attenuated and/or delayed by the pneumatic filtering effect of the cannula construct) and therefore it may be advantageous to supplement/replace this threshold pressure trigger with a pressure slope based triggering strategy based on a pattern of sloping pressure indicative of patient effort. Such a pressure slope based triggering strategy in the presence of significant signal attenuation can be more responsive (e.g., faster) to patient effort. It will be understood that to minimize the effects of the potentially attenuated/delayed pressure signal the downstream diameter of the combined NO/triggering lumen of cannulas of the present invention can be adjusted to widen (e.g., optimize) the band pass characteristics of the cannula; however, this may produce an undesirable side effect of the cannula nosepiece size being increased, which in turn may make the cannula less comfortable to the patient.
In exemplary embodiments, the upstream diameter of the combined NO/triggering lumen can be adjusted to widen the band pass characteristics of the cannula to ensure that unneeded compressible volume may be unavailable upstream of the nose piece restriction (e.g., 0.046 inch ID restriction, etc.). This can reduce the compressible volume in the cannula and/or effectively increases the band pass characteristics of the cannula.
In exemplary embodiments, triggering of dose delivery (e.g., by the delivery device) can be based on a pattern of sloping pressure indicative of patient efforts and/or the slope can be reduced in magnitude by the filtering characteristics of the tubing, however, the slope can still be present for algorithmic triggering decisions (e.g., by the delivery device). In exemplary embodiments, triggering methodologies can be based not on pressure thresholds, rather triggering methodologies can be based on pressure slope trends that can also be employed to improve overall timely delivery of dosing to the patient. It will be understood that such a triggering implementation can be optional.
Mono-Lumen Cannula
Referring to
In exemplary embodiments, a carrier gas can be used buffer (e.g., insulate) the NO from O2 and/or a carrier gas can be used to increase the effective volume of the delivered dose, for example, to reduce the transit time of NO in the cannula. This buffer gas can be diffused into the NO dose and/or surround the NO dose (e.g., spatially before and after).
Referring to
In exemplary embodiments, when using a buffer gas to transport the NO within the cannula the amount of contact between NO with O2 and the time of contact can be minimized without substantially distorting the shape of the NO pulse dose. In exemplary embodiments, the buffer gas can be substantially devoid of O2 such that it can act as a buffer to any entrained O2 and/or it can increase the volume of delivered gas thereby decreasing the time that the NO dose in the cannula. In exemplary embodiments, the buffer gas can include oxygen, however, the diameter of the cannula lumen can be small enough so that the cross section of the NO dose exposed to O2 can be minimized and/or the diameter can be large enough to ensure that the pulse shape of the dose may not be substantially distorted.
In exemplary embodiments, a buffer gas can be provided by using the O2 depleted gas mixture remaining after an oxygen concentrator system has removed the O2 from air.
It will be understood that the buffer disclosed can be used with any multi-lumen cannula (e.g., dual-lumen cannula, tri-lumen cannula, quad-lumen cannula, etc.) where NO and O2 may be delivered in the same lumen. For example, a dual lumen cannula can have a trigger lumen and combined NO/O2 lumen wherein NO may be intermittently pulsed into O2 with a buffer separating the NO and O2.
In exemplary embodiments, the inner diameter of the mono-lumen (e.g., combined NO/O2 lumen, combined NO/O2/Trigger lumen, etc.) can be configured to be substantially small, for example, to reduce residual gas mixing. As discussed above, lumens that include different functions (e.g., NO delivery, triggering, O2 delivery, etc.) can have competing metrics for optimization. For optimization, the dimensions of the cross-section of the mono-lumen can require a compromise between at least some of these competing metrics. For example, because the mono-lumen has a combined NO/triggering lumen and/or combined NO/O2/Trigger, the optimal geometry (e.g., shape, size, etc.) of the mono-lumen can require compromise between at least some competing metrics to, for example, deliver pulses and/or flows of NO early in the inspiratory phase, reduce pneumatic delays, reduce distortion of flow waveforms, reduce delay and/or distortion of pressure signals, reduce the volume of NO mixing at the nosepiece, and/or NO oxidation at the nosepiece. Considering at least the competing metrics for optimization, in at least some embodiments, the inner diameter of the mono-lumen (e.g., combined NO/O2 lumen, combined NO/O2/Trigger lumen, etc.) can be less than about 0.07 inches.
Dual-Lumen Cannula
Referring to
In exemplary embodiments, the lumen (e.g., of the dual-lumen cannula) that carries the nitric-oxide containing gas can have a substantially small inner diameter that may be smaller than the other lumen(s) (e.g., the triggering lumen, oxygen lumen, etc.). In at least these embodiments, having a substantially small inner diameter for the lumen that carries NO the cannula can reduce dilution by at least the following mechanisms: (i) minimizing mixing of oxygen and NO because of a reduction in retrograde flow into the small ID NO carrying lumen due to the smaller ID; (ii) minimizing the bulk volume of gas mixing because the volume of NO gas per unit length can be reduced by having a small ID NO caring lumen; and/or (iii) the small ID NO carrying lumen can produce a narrow jet of gas flow which can effectively minimize O2/NO mixing during NO delivery and/or can minimize O2/NO mixing during NO delivery until much further into the nasal cavity. Similar mechanisms for reducing dilution can be accomplished by reducing the ID of the lumen for NO delivery used in other multi-lumen cannulas described herein (e.g., tri-lumen cannulas, quad-lumen cannulas, etc.).
In exemplary embodiments, the diameter of the small lumen can be minimized such that it can be as small as reasonably possible without producing confounding upstream effects on the flow delivery mechanics of the device. For example, in one or more embodiments, the NO lumen may have an ID in the range from about 0.01 inches to about 0.10 inches and/or about 0.03 inches to about 0.08 inches. Further, in one or more embodiments, the oxygen lumen and/or trigger lumen (e.g., dedicated trigger lumen, etc.) may have an ID in the range from about 0.05 inches to about 0.20 inches and/or about 0.08 inches.
Referring to
The first lumen for carrying oxygen can be constructed with a lumen inner diameter geometry consistent with industry norms. For example, a nasal cannulas with rated 6 LPM oxygen delivery capacity can have an oxygen lumen inner diameter of approximately 0.08 inches at, or near, the nosepiece. Accordingly, in one or more embodiments, the oxygen lumen can have an inner diameter in the range of about 0.05 inches to about 0.20 inches and/or about 0.08 inches.
The second lumen for carrying NO and triggering can be constructed based on compromise of competing metrics (e.g., as discussed above). For example, because the second lumen combines carrying NO and triggering, the optimal geometry (e.g., shape, size, etc.) of the second lumen can require compromise between at least some competing metrics to, for example, deliver pulses and/or flows of NO early in the inspiratory phase, reduce pneumatic delays, reduce distortion of flow waveforms, reduce delay and/or distortion of pressure signals, reduce the volume of NO mixing at the nosepiece, and/or NO oxidation at the nosepiece. Considering at least the competing metrics for optimization, in at least some embodiments, the geometry of the combined NO/Trigger lumen of the dual-lumen cannula can be in the range of about 0.08 inches. In exemplary embodiments, the internal diameter of the second lumen can be dictated by volumetric dosing accuracy considerations, the second lumen can have an ID in the range of about 0.01 inches to about 0.10 inches, and/or the second lumen can have an ID in the range of about 0.01 inches to about 0.06 inches with upstream tubing that can be adjusted to optimize (e.g., widened, etc.) the band pass performance of the system.
In exemplary embodiments, a dual-lumen cannula can have a first lumen for NO delivery and a second lumen for delivery of O2 and transmitting the pressure signal for the trigger sensor of delivery device. In this configuration the NO lumen can be substantially small (e.g., having similar dimensions to the NO lumen described below in a tri-lumen cannula) and/or the combined O2 and triggering lumen can have an inner diameter in the range of about 0.07 inches to about 0.14 inches and/or about 0.03 inches to about 0.08 inches at the nosepiece. In exemplary embodiments, a dual-lumen cannula can have a first lumen for NO and O2 delivery and a second lumen for transmitting the pressure signal for the trigger sensor of delivery device. In this configuration, the first lumen for NO and O2 delivery can utilize similar techniques for delivering NO and O2 in the same lumen, for example, as described herein with reference to a mono-lumen cannula.
Tri-Lumen Cannula
Referring to
The NO lumen can be a dedicated lumen that can carry therapeutic gas comprising NO from NO delivery device 603 to the patient (e.g., via nares 610/612 at cannula nosepiece 602). The oxygen lumen can be a dedicated lumen that can carry an oxygen-enriched gas (e.g., such as oxygen-enriched air, substantially pure oxygen, etc.) from an oxygen source to the patient (e.g., via nares 610/612 at cannula nosepiece 602). The oxygen source can be an oxygen pulsing device (e.g., such as an oxygen conserver) and/or a constant flow oxygen device (e.g., such as an oxygen concentrator) and/or can be a port on the NO delivery device that delivers the oxygen-enriched gas. The trigger lumen can be a dedicated lumen that allows propagation of triggering signals from the patient to NO delivery device 603.
In exemplary embodiments, the nasal cannula can connect the oxygen lumen to an oxygen source (e.g., an oxygen pulsing device, an oxygen conserver, a constant flow oxygen device, oxygen concentrator, etc.) and/or the nasal cannula may not connect the oxygen lumen to an oxygen source (e.g., for patients who are not receiving supplemental oxygen). For patients who are not receiving supplemental oxygen, the oxygen lumen may be removed and/or may be partially removed. For example, the oxygen lumen may be partially preserved to support the oxygen side of the cannula which goes around the patient's head while the lumen portion providing the connection to an oxygen source (e.g., an oxygen pigtail off of the reducer) may be removed. Removal and/or partial removal of the oxygen lumen can similarly be done for other multi-lumen cannulas described herein (e.g., dual-lumen cannulas, quad-lumen cannulas, etc.).
Referring to
The three lumens can be extruded through a single die producing a multi-lumen tube, can be extruded in a single multicavity extrusion, can be extruded separately and affixed together in a paratube arrangement disclosed herein, and/or using any other reasonable technique. Similar techniques can be used for other multi-lumen cannulas described herein (e.g., dual-lumen cannulas, quad-lumen cannulas, etc.).
Referring to
The above can reduce the potential for retrograde flow, reduce the volume of retrograde flow, and/or reduce the contact and/or contact duration between NO and other gasses including oxygen in the cannula, to name a few. This in turn can reduce the dilution of NO and/or thereby increase the precision of the delivered NO dose. Accordingly, in exemplary embodiments, the ID of the NO lumen can be about 0.01 inches to about 0.10 inches and/or about 0.07 inches.
The ID of the NO lumen can decrease from a maximum ID to a minimum ID, for example, to at least reduce cross flow and/or increase patient comfort. In exemplary embodiments, the ratio of the minimum ID to the maximum ID of the NO lumen can be, but is not limited to, 1:1, 1:1.2, 1:1.3, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:7, 1:8, 1:9, and/or 1:10, to name a few. Similar ratios of the minimum ID to the maximum ID of the NO lumen can be used for other multi-lumen cannulas (e.g., dual-lumen, tri-lumen, quad-lumen cannula, etc.) described herein that can have dedicated lumens for NO delivery and/or combined NO delivery and triggering lumens.
The trigger lumen ID can be comparatively much larger than the NO lumen ID. The trigger lumen ID can be substantially larger so that trigger pressure drop on inhalation can be transmitted through this cannula lumen with the smallest possible loss of signal magnitude and/or phase delay to the NO delivery device which in turn can use this pressure signal to deliver pulsed NO. Accordingly, in exemplary embodiments, the ID of the trigger lumen can be about 0.05 inches to about 0.20 inches and/or about 0.08 inches. In exemplary embodiments, the ratio of the ID of the NO lumen to the ID of trigger lumen can be, but is not limited to, 1:1, 1:1.2, 1:1.3, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:12, 1:15, 1:20, 1:25, and/or 1:30, to name a few.
The oxygen lumen can also be larger than the NO lumen, for example, to minimize oxygen flow resistance and/or to reduce gas flow speed at the nares which can serve to interfere with the triggering pressure signal due to gas flow effects (e.g., such as from Bernoulli's principle) and/or to reduce high frequency (e.g., auditory range) resonance with high speed oxygen transit to reduce the “noise” associated with oxygen delivery. Accordingly, in exemplary embodiments, the ID of the oxygen lumen can be about 0.05 inches to about 0.20 inches and/or about 0.08 inches. In exemplary embodiments, the ratio of the ID of the NO lumen to the ID of the oxygen lumen can be, but is not limited to, 1:1, 1:1.2, 1:1.3, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:12, 1:15, 1:20, 1:25, and/or 1:30, to name a few.
Quad-Lumen Cannula
Referring to
In exemplary embodiments, like the pneumatic configurations discussed above, this configuration can separate the pneumatic paths of the NO, oxygen, and trigger. Further, in exemplary embodiments, the NO flow delivery paths to each nostril can be kept separate and distinct and/or have their own pneumatic delivery source at the NO delivery device.
Referring to
In exemplary embodiments, the dimensions of the triggering lumen 806, oxygen lumen 808, NO lumens 804A and 804B can be similar to the respective lumens in the tri-lumen cannula and/or the geometry of these lumens can provide similar benefits as those described above with respect to the tri-lumen cannula.
Further to the above benefits, the quad-lumen cannula configuration can, amongst other things, prevent movement of gas through the connected (e.g., tee'd) delivery loop of the NO supply line during exhalation. This can reduce NO/oxygen contact and/or reduce or substantially eliminate cross flow. In at least some instances, use of the quad-lumen cannula can require dedicated pneumatic circuitry for each NO lumen.
In exemplary embodiments, the quad lumen cannula configuration can include two triggering lumens (e.g., one two each nostril) as well as an NO delivery lumen and an O2 delivery lumen. Of course other configurations are within the scope of the invention.
Check Valves and Valves
In one or more embodiments, a nasal cannula (e.g., single lumen cannula, multi-lumen cannula, any of the nasal cannulas disclosed herein, etc.) can include one or more check valves that can be located in, and/or in fluid communication with, the nitric oxide delivery line. Further, in exemplary embodiments, one or more check valves located in, and/or in fluid communication with, the nitric oxide delivery line can be combined with any of the multi-lumen configurations described. Check valves can be used to, amongst other things, prevent retrograde gas movement into the NO supply lumen during inhalation/exhalation. Check valves can be any low cracking pressure check valve which can be placed at some point in, and/or in fluid communication with, the NO delivery path. Such check valves can include, but are not limited to, duckbill valves, umbrella valves, and/or any other valve.
Referring to
Referring to
In one or more embodiments, the nasal cannula can incorporate an impermeable and/or semi-permeable membrane that can be movable or fixed and/or can be actively or passively moved when needed. Further, the membrane can separate the NO containing gas or material from the O2 containing gas or material, for example, until the NO needs to be delivered to the patient. This membrane can reduce the contact time, surface area, and/or diffusion rate between the NO and O2 containing gases. This can reduce the formation of NO2, which can dilute the intended NO delivery concentration.
Referring to
In one or more embodiments, a system can be used and/or provided to expel the gas or other NO containing material that come in contact with O2 containing gas or material, which can have otherwise formed NO2 in this mixture. The system can subsequently allow another part of the NO containing gas or material that has minimal or no NO2 to be delivered to the patient.
Referring to
It will be understood that the any of above teachings (e.g., check valves, check valve configurations, membranes, valves, electromechanical valve systems, etc.) can be combined with any of the other pneumatic configurations, cannula configurations, and/or teachings and/or embodiments described herein. For example, the above teachings (e.g., check valve configurations, etc.) can be used with the mono-lumen cannulas or multi-lumen cannulas described herein and/or any other teachings and/or embodiments described herein.
Minimizing NO/O2 Contact During Connection to Source
One or more embodiments of the present invention relate to nasal cannulas and/or systems that reduce NO/O2 contact during the connection of the high pressure source (e.g., a pressurized cylinder, etc.) to the delivery device (e.g., one or more of the above sources of oxygen/NO contact) and thereby dilution of the intended NO dose using a three way valve. For example, nasal cannulas and/or systems of the present invention can include a three way valve with one port to ambient that can be configured so that the three way valve opens to ambient upon connection of the canister to remove (e.g., blow off) the oxygen.
Proportional Nostril Delivery
Referring to
This inadequate dosing can be a particular problem when delivering the drug therapy in set limited quantities, such as when pulsed (e.g., when delivered synchronous to a patient's breathing pattern and rhythm) through a single lumen exiting the delivery device that in turn may then be split at some point downstream before reaching the patient. Further, this can be a particular problem because, when pulsing the drug dose through a single lumen that is then split, the dose can be equally or substantially equally split in the two streams without consideration for the blockage in the nose downstream of the split. Thus a significant part (e.g., up to half) of the dose may not be delivered to the patient and/or may remain in the vicinity of the blocked or obstructed nares.
One or more embodiments of the present invention relate to nasal cannulas and/or systems that solves or minimize the above problem by, for example, providing for the roughly proportional delivery of the therapy to each nares with the delivery being proportional to the flow of air and gas in the nares and/or inversely proportional to the resistance in the nares. This can be achieved by using the driving force of the patient's breathing, which can be generally and roughly proportional to the flow rate of air/gas into each of the nares, to proportionally split and/or pull the therapy gas into the patient's nose and subsequently into the patient's lungs. This system can deliver the dose to a patient in such a way as to ensure that the designed, set, or adequate dose can be delivered proportional to the flow of air in each nostril (or inversely proportional to the resistance of each nostril) such that the partial or full blockage (whether permanent or transient) of either or both nostril doesn't affect the amount of drug delivered to the patient.
For example, the cannula/lumen can be designed to deliver a desired quantity of the therapeutic gas such that the delivered dose can be injected and/or delivered into a flowing stream of inspiratory air, driven by the patient's breathing, with such flow splitting, downstream of the point of delivery of the drug, proportional to the amount of air going into each nostril or simply delivered to one nostril if the other nostril's flow is below a predetermined threshold such that the delivered drug can also be split proportional and/or roughly proportional or directed to one or the other nostril in an all or none configuration based on the higher flowing nostril to the said flow of gas. The flow of air in a stream to the patient can be achieved by having a flow path from the ambient air (e.g. through a simple hole in the nose piece of the cannula) to each nostril such that this flow path crosses the delivery point/area/volume of the drug before moving on to the split point leading to each nostril.
In exemplary embodiments, exemplary cannula/lumen configurations can allow the NO delivery to each nostril by injecting NO into a flow of ambient air going to each nostril (e.g., as shown in
Independent Nostril Delivery
One or more embodiments of the present invention relate to nasal cannulas and/or systems that address the problem of inadequate dosing due to a partially or completely blocked nostril by, for example, detecting and/or determining the amount of driving force in each nostril and adjusting the amount of drug delivered to each of the nares. This can be accomplished by using valves, baffles, flaps, and/or any other device to ensure proportional and/or substantially proportional dosing in each nostril.
Addressing at least the above, dual channel systems (e.g., that may work with multi-lumen cannulas such as quad-lumen cannulas) can utilize at least two independent flow channels: one to each nostril. In exemplary embodiments, these independent flow channels can have drug flows tailored to the inspiratory draw of each nostril, for example, by configuring the flow channels to deliver flow proportional to the draw of each nostril with total flow to both nostrils summing to the appropriate dose and/or by configuring the flow channels to deliver to the single working (e.g., high flow draw nostril) if the flow draw of the occluded nostril falls below a preset threshold.
Referring to
Referring to
In exemplary embodiments, the pneumatics channels can be controlled by a controller and/or an embedded (global) controller module that can be capable of independent control of both channels, for example, to ensure proper overall dosing. This controller can receive input from the pressure or flow sensor(s) (e.g., two separate pressure sensors, a single pressure sensor that can obtain the two pressure measurements in isolation, etc.) and can control both solenoid valves to achieve the proper dosing regimen.
Manufacturing of Multi-Lumen Nasal Cannulas
As described above, the individual lumen of a multi-lumen cannula can be separately manufactured and then affixed to each other (e.g., paratube arrangement, etc.) and/or the multiple lumina can be extruded through a single die producing a multi-lumen tube.
According to one or more embodiments, the multi-lumen nosepiece of the multi-lumen cannulas described herein can be manufactured using molding techniques. For example, the cannula can be manufactured to have a triple lumen cannula nosepiece for separate oxygen, nitric oxide, and triggering lumina.
Referring to
Referring to
In exemplary embodiments, to circumvent the injector pin limitation with the small ID lumen being defined by indents in the halves, the two halves can be molded flat in one shot, for example, with a webbing (e.g., webbing 1709) holding the halves together and providing gross alignment during the folding and bonding process. The molded halves can, in some instances, include integral holes and mating cylindrical tabs or other complementary members (e.g., tab 1710 and tab mate 1712) so that the halves can be properly aligned when folded together. The webbing can also be optional, for example, if appropriate complementary indexing members on the two halves ensure that the two portions forming the outer wall of the NO lumen can be properly aligned. The assembled nosepiece can allow for three lumen inputs and can be connected (e.g., tee'd) to each lumen input within the internals of the nosepiece proper. Of course the nosepiece can be constructed using any reasonable technique. By way of example, a nosepiece with a substantially small NO lumen can also be constructed using liquid silicon rubber injection molding (e.g., a low pressure molding technique in which a more robust mold tool may be achieved), and/or using a low pressure molding technique. Further, a nosepiece with a substantially small NO lumen can be constructed using micromolding techniques known in the art which may be used for high resolution production of small parts including parts with small mold pins. By way of example a nosepiece with a substantially small NO lumen can be constructed using micro-molding techniques known in the art.
Referring to
The lumen ID can be adjusted as described above. For example, the ID of the oxygen lumen can range from about 0.05 inches to about 0.20 inches, the ID of the trigger lumen can range from about 0.05 inches to about 0.20 inches, and the ID of the NO lumen can range from about 0.01 inches to about 0.10 inches. In one or more embodiments, the IDs of the oxygen lumen and the trigger lumen can both be in the range from about 0.07 inches to about 0.09 inches and/or about 0.08 inches and the ID of the NO lumen can be in the range from about 0.035 inches to about 0.055 inches and/or about 0.045 inches.
Referring to
Exemplary Nasal Cannula
Referring to
Referring to
Referring to
Referring to FIGS. 20 and 22A-22E, nasal cannula connection piece 2014 can be constructed to ensure fluid communication between the patient and the device. The connection piece can be plugged into the device and/or can be designed such that unidirectional connection may be required (e.g., such that it cannot be installed backwards). Further the connection piece can include additional features such as, but not limited to, a color stamped and/or differentially reflective area that can be used with IR sensing/detection to confirm insertion and/or the connection piece can include a strain relief component 2202 (e.g., as shown in
Referring to
Referring to
In exemplary embodiments, tubes (e.g., NO lumen 2003, trigger lumen 2004, oxygen lumen 2008, combined lumens, etc.) can be attached to cannula nosepiece 2002 and/or device connector (e.g., connection pieces 2014 and 2016) using any technique such as, but not limited to, bonding, adhesives (e.g., epoxy, cyanoacrylate, etc.), solvent bonding, insert molding, and/or by any other technique.
Referring to
Nosepiece
Referring to
In exemplary embodiments, the cannula nosepiece and/or at least some of the cannula nosepiece and/or cannula can have a material properties (e.g., durometer, etc.) selected to provide the comfort while ensuring the structural and pneumatic integrity (e.g., of the cannula nosepiece, at least some of the cannula nosepiece, at least some of the cannula, etc.). For example, to provide comfort while ensuring structural and pneumatic integrity, the cannula nosepiece and/or at least some of the cannula nosepiece and/or cannula can have about 30 to 70 durometer and/or about 50 durometer (Shore A).
In exemplary embodiments, cannula nosepiece 2002 can include three lumens in a “tornado” 2515 design that can allow sufficient rigidity for the nasal nares, yet allows the nares to be partially compressible, for example, because the dividing lines for the oxygen lumen 2008 and triggering lumens 2004 can be offset (e.g., not aligned through the center of the NO delivery lumen 2003). This compressibility can allow for the nasal prong to be more flexible and comfortable than other tri-lumen cannula prong designs.
In exemplary embodiments, the tornado can also encapsulate the smaller NO lumen 2004, the nasal nares can be designed to ensure optimal and/or a desired insertion distance, and/or to increase comfort the nasal cannula can be tapered from base to end and/or can be arcuate (e.g., inwards towards the nasal openings). In exemplary embodiments, this optimal and/or desired insertion distance can be about 0.1 inches to about 0.6 inches and/or about 0.40 inches.
In exemplary embodiments, the outlet geometry of the oxygen lumen (e.g., at the cannula nosepiece) can be designed to reduce auditory frequency noise (e.g., about 20 hz to 15 khz) by, for example, tapering of the outlet of the oxygen lumen. Further, noise reduction can also be achieved by modification of the durometer of the oxygen carrying lumen to prevent auditory range oscillation and noise due to oxygen flow and/or by selecting a geometry of the oxygen lumen that does not generate noise (e.g., vibration, resonance, etc.).
Referring to
In exemplary embodiments, the outer diameter of the cannula nosepiece nares can be minimized to increase patient comfort. Taking into account this outer dimension, the dimensions of the various lumens (e.g., trigger lumen, NO lumen, O2 lumen, etc.) can be selected to not only be optimized (e.g., as discussed herein) but can also be limited in size to account for patient comfort. For example, although it may be beneficial for optimization to have nares with a larger outer diameter (e.g., an outer diameter of about 0.25 inches or larger), the nares of the cannula may have an outer diameter of less than and/or about 0.2 inches for patient comfort.
By way of example, taking into account patient comfort as well as at least some and/or all of the metrics for optimization disclosed herein, a tri-lumen cannula (e.g., with a length of about 7 feet) can have tubing with an NO lumen having an ID of about 0.069 inches, a trigger lumen having an ID of about 0.089 inches, and an O2 lumen having an ID of about 0.089 inches with at least some of the lumens reducing at the cannula nosepiece (e.g., having a backplane length of about 0.59 inches) and/or reducing (e.g., reducing again) at the nares (e.g., having a length of about 0.47 inches) of the cannula nosepiece. For example, at the cannula nosepiece the NO lumen can be reduced to an ID of about 0.049 inches, the trigger lumen can have an ID of about 0.089 inches, and/or the O2 lumen can have an ID of about 0.089 inches. Still following the above example, at the nares of cannula nosepiece the NO lumen can be reduced to an ID of about 0.038 inches, the trigger lumen can be reduced to an ID of about 0.079 inches, and/or the O2 lumen can be reduced to an ID of about 0.079 inches. Further, prior to the reducer and/or connection piece the NO lumen can have an ID of about 0.069 inches, the trigger lumen can have an ID of about 0.089 inches, and the O2 lumen can have an ID of about 0.132 inches.
By way of example, taking into account patient comfort as well as at least some and/or all of the metrics for optimization disclosed herein, a tri-lumen cannula (e.g., with a length of about 3 feet) can have tubing with an NO lumen having an ID of about 0.064 inches, a trigger lumen having an ID of about 0.084 inches, and an O2 lumen having an ID of about 0.084 inches with at least some of the lumens reducing at the cannula nosepiece (e.g., having a backplane length of about 0.59 inches) and/or reducing (e.g., reducing again) at the nares (e.g., having a length of about 0.47 inches) of the cannula nosepiece. For example, at the cannula nosepiece the NO lumen can be reduced to an ID of about 0.044 inches, the trigger lumen can have an ID of about 0.084 inches, and/or the O2 lumen can have an ID of about 0.084 inches. Still following the above example, at the nares of cannula nosepiece the NO lumen can be reduced to an ID of about 0.036 inches, the trigger lumen can be reduced to an ID of about 0.074 inches, and/or the O2 lumen can be reduced to an ID of about 0.074 inches. Further, prior to the reducer and/or connection piece the NO lumen can have an ID of about 0.064 inches, the trigger lumen can have an ID of about 0.084 inches, and the O2 lumen can have an ID of about 0.127 inches.
By way of example, taking into account patient comfort as well as at least some and/or all of the metrics for optimization disclosed herein, a tri-lumen cannula (e.g., with a length of about 15 feet) can have tubing with an NO lumen having an ID of about 0.074 inches, a trigger lumen having an ID of about 0.094 inches, and an O2 lumen having an ID of about 0.094 inches with at least some of the lumens reducing at the cannula nosepiece (e.g., having a backplane length of about 0.59 inches) and/or reducing (e.g., reducing again) at the nares (e.g., having a length of about 0.47 inches) of the cannula nosepiece. For example, at the cannula nosepiece the NO lumen can be reduced to an ID of about 0.054 inches, the trigger lumen can have an ID of about 0.094 inches, and/or the O2 lumen can have an ID of about 0.094 inches. Still following the above example, at the nares of cannula nosepiece the NO lumen can be reduced to an ID of about 0.04 inches, the trigger lumen can be reduced to an ID of about 0.084 inches, and/or the O2 lumen can be reduced to an ID of about 0.084 inches. Further, prior to the reducer and/or connection piece the NO lumen can have an ID of about 0.074 inches, the trigger lumen can have an ID of about 0.094 inches, and the O2 lumen can have an ID of about 0.137 inches.
By way of example, taking into account patient comfort as well as at least some and/or all of the metrics for optimization disclosed herein, a quad-lumen cannula (e.g., with a length of about 7 feet) can have tubing with at least one NO lumen having an ID of about 0.069 inches, at least one trigger lumen having an ID of about 0.089 inches, and an O2 lumen having an ID of about 0.089 inches with at least some of the lumens reducing at the cannula nosepiece (e.g., having a backplane length of about 0.59 inches) and/or reducing (e.g., reducing again) at the nares (e.g., having a length of about 0.47 inches) of the cannula nosepiece. For example, at the cannula nosepiece the NO lumen(s) can be reduced to an ID of about 0.049 inches, the trigger lumen(s) can have an ID of about 0.089 inches, and/or the O2 lumen can have an ID of about 0.089 inches. Still following the above example, at the nares of cannula nosepiece the NO lumen(s) can be reduced to an ID of about 0.038 inches, the trigger lumen(s) can be reduced to an ID of about 0.079 inches, and/or the O2 lumen can be reduced to an ID of about 0.079 inches. Further, prior to the reducer and/or connection piece the NO lumen(s) can have an ID of about 0.069 inches, the trigger lumen(s) can have an ID of about 0.089 inches, and the O2 lumen can have an ID of about 0.132 inches.
By way of example, taking into account patient comfort as well as at least some and/or all of the metrics for optimization disclosed herein, a quad-lumen cannula (e.g., with a length of about 3 feet) can have tubing with at least one NO lumen having an ID of about 0.064 inches, at least one trigger lumen having an ID of about 0.084 inches, and an O2 lumen having an ID of about 0.084 inches with at least some of the lumens reducing at the cannula nosepiece (e.g., having a backplane length of about 0.59 inches) and/or reducing (e.g., reducing again) at the nares (e.g., having a length of about 0.47 inches) of the cannula nosepiece. For example, at the cannula nosepiece the NO lumen(s) can be reduced to an ID of about 0.044 inches, the trigger lumen(s) can have an ID of about 0.084 inches, and/or the O2 lumen can have an ID of about 0.084 inches. Still following the above example, at the nares of cannula nosepiece the NO lumen(s) can be reduced to an ID of about 0.036 inches, the trigger lumen(s) can be reduced to an ID of about 0.074 inches, and/or the O2 lumen can be reduced to an ID of about 0.074 inches. Further, prior to the reducer and/or connection piece the NO lumen(s) can have an ID of about 0.064 inches, the trigger lumen(s) can have an ID of about 0.084 inches, and the O2 lumen can have an ID of about 0.127 inches.
By way of example, taking into account patient comfort as well as at least some and/or all of the metrics for optimization disclosed herein, a quad-lumen cannula (e.g., with a length of about 15 feet) can have tubing with at least one NO lumen having an ID of about 0.074 inches, at least one trigger lumen having an ID of about 0.094 inches, and an O2 lumen having an ID of about 0.094 inches with at least some of the lumens reducing at the cannula nosepiece (e.g., having a backplane length of about 0.59 inches) and/or reducing (e.g., reducing again) at the nares (e.g., having a length of about 0.47 inches) of the cannula nosepiece. For example, at the cannula nosepiece the NO lumen(s) can be reduced to an ID of about 0.054 inches, the trigger lumen(s) can have an ID of about 0.094 inches, and/or the O2 lumen can have an ID of about 0.094 inches. Still following the above example, at the nares of cannula nosepiece the NO lumen(s) can be reduced to an ID of about 0.04 inches, the trigger lumen(s) can be reduced to an ID of about 0.084 inches, and/or the O2 lumen can be reduced to an ID of about 0.084 inches. Further, prior to the reducer and/or connection piece the NO lumen(s) can have an ID of about 0.074 inches, the trigger lumen(s) can have an ID of about 0.094 inches, and the O2 lumen can have an ID of about 0.137 inches.
By way of example, taking into account patient comfort as well as at least some and/or all of the metrics for optimization disclosed herein, a dual-lumen cannula (e.g., with a length of about 7 feet) can have tubing with a combined NO/trigger lumen having an ID of about 0.07 inches and an O2 lumen having an ID of about 0.089 inches with at least some of the lumens reducing at cannula nosepiece (e.g., having a backplane length of about 0.59 inches) and/or reducing (e.g., reducing again) at the nares (e.g., having a length of about 0.47 inches) of the cannula nosepiece. For example, at the cannula nosepiece the combined NO/trigger lumen can be reduced to an ID of about 0.05 inches and/or the O2 lumen can have an ID of about 0.089 inches. Still following the above example, at the nares of cannula nosepiece the combined NO/trigger lumen can be reduced to an ID of about 0.04 inches and/or the O2 lumen can be reduced to an ID of about 0.079 inches. Each of these dimensions for the combined NO/trigger lumen may be increased slightly (e.g., by a few thousands), for example, to reduce trigger signal attenuation. Further, prior to the reducer and/or connection piece the combined NO/trigger lumen can have an ID of about 0.07 inches, and the O2 lumen can have an ID of about 0.132 inches.
By way of example, taking into account patient comfort as well as at least some and/or all of the metrics for optimization disclosed herein, a dual-lumen cannula (e.g., with a length of about 3 feet) can have tubing with a combined NO/trigger lumen having an ID of about 0.064 inches and an O2 lumen having an ID of about 0.084 inches with at least some of the lumens reducing at the cannula nosepiece (e.g., having a backplane length of about 0.59 inches) and/or reducing (e.g., reducing again) at the nares (e.g., having a length of about 0.47 inches) of the cannula nosepiece. For example, at the cannula nosepiece the combined NO/trigger lumen can be reduced to an ID of about 0.044 inches and/or the O2 lumen can have an ID of about 0.0.084 inches. Still following the above example, at the nares of cannula nosepiece the combined NO/trigger lumen can be reduced to an ID of about 0.036 inches and/or the O2 lumen can be reduced to an ID of about 0.074 inches. Each of these dimensions for the combined NO/trigger lumen may be increased slightly (e.g., by a few thousands), for example, to reduce trigger signal attenuation. Further, prior to the reducer and/or connection piece the combined NO/trigger lumen can have an ID of about 0.064 inches, and the O2 lumen can have an ID of about 0.127 inches.
By way of example, taking into account patient comfort as well as at least some and/or all of the metrics for optimization disclosed herein, a dual-lumen cannula (e.g., with a length of about 15 feet) can have tubing with a combined NO/trigger lumen having an ID of about 0.074 inches and an O2 lumen having an ID of about 0.094 inches with at least some of the lumens reducing at cannula nosepiece (e.g., having a backplane length of about 0.59 inches) and/or reducing (e.g., reducing again) at the nares (e.g., having a length of about 0.47 inches) of the cannula nosepiece. For example, at the cannula nosepiece the combined NO/trigger lumen can be reduced to an ID of about 0.054 inches and/or the O2 lumen can have an ID of about 0.094 inches. Still following the above example, at the nares of cannula nosepiece the combined NO/trigger lumen can be reduced to an ID of about 0.040 inches and/or the O2 lumen can be reduced to an ID of about 0.084 inches. Each of these dimensions for the combined NO/trigger lumen may be increased slightly (e.g., by a few thousandths of an inch), for example, to reduce trigger signal attenuation. Further, prior to the reducer and/or connection piece the combined NO/trigger lumen can have an ID of about 0.074 inches, and the O2 lumen can have an ID of about 0.137 inches.
Trampoline
In exemplary embodiments, cannula nosepiece 2002 can include a flexible support bridge or “trampoline” 2517 that can cushion the nasal septum. Flexible support bridge 2517 can provide increased patient comfort by, for example, increasing the surface area of contact between the cannula and the nasal septum and/or patient comfort can be increased because the prong bridge can be designed to deflect away from the nasal septum.
In exemplary embodiments, flexible support bridge 2517 can be an element (e.g., free floating element) that may be supported on both ends by the prongs of the nasal cannula. Rather than having a patient nose (e.g., nasal septum) rest on a central bridge member 2518 commonly found in nasal cannulas (e.g., that separates the nares of a nasal cannula; a hard plastic connection, sometimes curved, between the nares of a nasal cannula; etc.) flexible support bridge 2517 can be an element (e.g., additional to central bridge 2518, traversing at least some of central bridge 2518, traversing from one nare to another nare, etc.) contacting the patient's septum thereby providing at least increased comfort to the patient. In exemplary embodiments, flexible support bridge 2517 can “give” and/or “bend” towards central bridge member 2518 when the cannula is worn. The “give” and/or “bending” of flexible support bridge 2517 can smooth transient forces on the nasal septum due to patient movement or cannula movement. The “give” and/or “bending” can also increase surface area of contact with the nasal septum, which in turn can reduce the force on the nasal septum at any one point thereby improving comfort (e.g., as comfort may be adversely affected by increasing point load on the nasal septum).
In exemplary embodiments, flexible support bridge 2517 can restrict the depth of insertion of the nasal nares, for example, as mentioned above, to an optimal and/or desired insertion distance of about 0.1 inches to about 0.6 inches and/or about 0.40 inches. By way of example, this distance can be shorter than the nasal nares length extending from central bridge 2518.
In exemplary embodiments, the nasal cannula nosepiece can include a tab 2519 between the nares (e.g., extending from central bridge 2518) that can allow the nasal cannula connection piece to sit properly on the upper lip. Tab 2519 can provide an additional measure of patient comfort by, for example, orienting the nares so the nares point inwards towards the nostril openings and/or can distribute force on the upper lip over a larger surface area thereby improving patient comfort.
Referring to
In exemplary embodiments, the nasal cannula can further include ear pads that can, for example, slide over and/or be built into the cannula tubing at the point where the cannula tubing wraps the ears to improve comfort and/or the ear pads can be foam tube extrusions which may have axial slits so they can slide over the cannula tubing.
Although this exemplary nasal cannula may be described as having certain components, any and all of these components may be optional, may be eliminated, and/or can be combined and/or further separated. Furthermore, the nasal cannula may have any of the other components or materials otherwise described herein.
Cannula Keying
During the purging and/or washout procedure that can be used to clear the nasal cannula of air and other gases prior to NO delivery, air/gases can be purged by flowing NO-containing gas through the nasal cannula. However, due to the reaction of NO and the oxygen in the air, this washout procedure can produce NO2. Accordingly, it can be important that the patient not be wearing the nasal cannula during the purging and/or washout procedure, for example, so that the NO2 cannot be administered to the patient.
Referring back to
Referring to
In one or more exemplary implementations of a NO delivery device with a keyhole and a nasal cannula with a keying element, the NO delivery device can perform the following functions:
In exemplary embodiments, the keying element and/or key slot can be used to ensure that the patient is not wearing the nasal cannula during the purging and/or washout procedure. In exemplary embodiments, the keying element and/or key slot can be used to ensure authenticity of at least the cannula, expiration of at least the cannula. For example, the keying element and/or key slot can be used to limit the number of cannula uses and/or not allow patients to re-use the cannula. For another example, in the event of a need to ensure patients not use the cannula, the keying element and/or key slot can be used prevent users from using defected cannula.
It will be understood that any of the above teachings (e.g., trampoline, tab, paratube, connection piece, oxygen connection piece, reducer, keying member, keying, bolo, cannula constructs, nosepiece constructs, etc.) can be combined with any of the other pneumatic configurations, cannula configurations, and/or teachings and/or embodiments described herein. For example, the above teachings (e.g., trampoline, tab, paratube, connection piece, oxygen connection piece, reducer, keying member, keying, bolo, cannula constructs, nosepiece constructs, etc.) can be used with mono-lumen cannulas, dual-lumen cannulas, tri-lumen cannulas, quad-lumen cannulas, and/or any other teachings and/or embodiments described herein.
Referring to
Referring to
The document attached to U.S. Provisional Application No. 61/856,367, filed Jul. 19, 2013 as Appendix 1, titled “Exploratory Evaluation of Nitrogen Dioxide Formation in Candidate Nitric Oxide Delivery Lumena,” examined the concentration of NO2 anticipated to be present in the iNO delivery lumen of tri-lumen cannulas made of various materials. Appendix 1 attached to U.S. Provisional Application No. 61/856,367, filed Jul. 19, 2013 is incorporated by reference herein in its entirety; to the extent it is not inconsistent with the present invention. The experimental technique involved the flowing of 2440 ppm nitric oxide (balance nitrogen) gas through multiple tubes (of three material types) arranged in parallel such that proximal (based on the circuit without the tubes) and distal readings of the effluent NO2 content could be taken using a CAPs NO2 bench. Parallel tubes were used to improve the signal-to-noise ratio (i.e. to magnify the NO2 signal strength) of the data and a final mathematical calculation of individual tube NO2 change was obtained. The flow of nitric oxide through the parallel tubing banks was set to equate to a residence time of 7.57 min/tube (e.g., based on a 50 kg patient with dosing set to 0.003 mg/kg*hr with an iNO delivery tube of 84 inches length and 0.076 inches inner diameter). The “per tube” expected NO2 rise for the three material types tested is shown in below.
Methods of Treatment
The invention herein can reduce retrograde flow, ensure accurate dose delivery, and/or minimize NO2 formation and used in conjunction with a delivery device can be used for the treatment and or prevention of Pulmonary hypertension secondary to COPD and/or Pulmonary hypertension as PAH and/or Pulmonary hypertension secondary to IPF and/or Pulmonary hypertension secondary to sarcoidosis.
For safe and effective use the disclosed cannula may be used with the disclosed delivery device, and the like, and/or nitric oxide. One skilled in the art will appreciate that using a cannula other than the disclosed cannula along with the disclosed delivery device, and the like, and/or nitric oxide may increase safety risks and/or reduce and/or eliminate effective use. Accordingly, the cannula of present invention may be necessary for delivering nitric oxide for PAH, IPF, and/or COPD.
Any of the nasal cannulas described herein can be used in nitric oxide therapy to treat appropriate diseases. For example, the cannulas can be for pulsed NO therapy to treat chronic obstructive pulmonary disease (COPD) or pulmonary arterial hypertension (PAH). For these diseases, the delivery of the appropriate dose amounts and appropriate dose timing may be very important. For COPD, the NO may need to be pulsed early in inspiration, such as the first half of inspiration. If NO is, for example, not delivered in the right amount or at the right time, reversal of hypoxic vasoconstriction can occur, which could worsen the patient's condition. Furthermore, the dose amount can be very important for PAH because sudden discontinuation of therapy can lead to serious events such as rebound hypertension. Thus, significant dilution of the NO dose should be minimized for these diseases. Any of the cannula materials, configurations or methods described herein can be used to minimize dilution of the NO dose during NO therapy.
In exemplary embodiments, lumens (e.g., tubes) of the cannula can carry backwards towards the patient and/or can be affixed to each other so as to produce a substantially singular element umbilical between the cannula nosepiece and the device, which can provide a cross-section. It will be understood that when describing a plurality of lumens (e.g., two lumens, three lumens, four lumens, etc.) all of the lumens can be included in a single cannula.
In exemplary embodiments, elements of the cannula can be manufactured using any of the techniques disclosed herein and/or using techniques known in the art. For example, cannula lumens (e.g., tubes), nosepiece, key member, connectors, reducers, any combination and/or further separation thereof, and/or any element of cannulas described herein can be manufacturing using extrusion techniques, molding techniques, and/or using any other manufacturing technique.
It will be understood that the each lumen the nasal cannula and/or collective nasal cannula lumen cross-section can be any shape such as, but not limited to, to circular, parabolic, ellipsoidal, square, rectangular, triangular, and/or any other cross-section and/or or any other regular or irregular shape to minimize dose dilution. For ease, at times the geometry and/or cross-section is described as circular, parabolic, and/or ellipsoidal and/or the cross-section is described as a diameter, inner diameter, or the like. This is merely for ease and is in no way meant to be a limitation. When one or more cross-sectional areas are not circular, then the ratio of inner diameters can be the square root of the ratio of the surface areas of the two lumina sections.
It will be understood that any of the above can be used for pulsed and/or non-pulsed delivery of a therapeutic gas (e.g., NO). For example, any of the above embodiments referencing pulsed delivery of a therapeutic gas, when applicable, can be used with non-pulsed delivery of a therapeutic gas, and vice versus. For ease, at times, reference may be made to pulsed or non-pulsed. This is merely for ease and is in no way meant to be a limitation.
Reference throughout this specification to “one embodiment,” “certain embodiments,” “one or more embodiments,” “exemplary embodiment,” “exemplary embodiments,” and/or “an embodiment” means that a particular feature, structure, material, or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. Thus, the appearances of the phrases such as “in one or more embodiments,” “in certain embodiments,” “in one embodiment,” “exemplary embodiment,” “exemplary embodiments,” and/or “in an embodiment” in various places throughout this specification are not necessarily referring to the same embodiment of the invention. Furthermore, the particular features, structures, materials, or characteristics can be combined in any suitable manner in one or more embodiments.
It will be understood that any of the steps described can be rearranged, separated, and/or combined without deviated from the scope of the invention. For ease, steps are, at times, presented sequentially. This is merely for ease and is in no way meant to be a limitation.
Further, it will be understood that any of the elements and/or embodiments of the invention described can be rearranged, separated, and/or combined without deviated from the scope of the invention. For ease, various elements are described, at times, separately. This is merely for ease and is in no way meant to be a limitation.
Although the disclosure herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It will be apparent to those skilled in the art that various modifications and variations can be made to the method and apparatus of the present invention without departing from the spirit and scope of the invention. Thus, it is intended that the present invention include modifications and variations that are within the scope of the appended claims and their equivalents.
| Number | Name | Date | Kind |
|---|---|---|---|
| 759152 | Bennett | May 1904 | A |
| 1369631 | De Vilbiss | Feb 1921 | A |
| 1443820 | Hudson | Jan 1923 | A |
| 1856811 | Inaki | May 1932 | A |
| 2860634 | Duncan et al. | Nov 1958 | A |
| 2931358 | Sheridan | Apr 1960 | A |
| 3260258 | Berman | Jul 1966 | A |
| 3513844 | Smith | May 1970 | A |
| 3682171 | Dali et al. | Aug 1972 | A |
| 3867946 | Huddy | Feb 1975 | A |
| 3877436 | Havstad | Apr 1975 | A |
| 3882259 | Nohara et al. | May 1975 | A |
| 3915173 | Brekke | Oct 1975 | A |
| 3951175 | Eberhart | Apr 1976 | A |
| 3972321 | Proctor | Aug 1976 | A |
| 4015366 | Hall, III | Apr 1977 | A |
| 4015598 | Brown | Apr 1977 | A |
| 4054133 | Myers | Oct 1977 | A |
| 4082854 | Yamada et al. | Apr 1978 | A |
| 4151843 | Brekke et al. | May 1979 | A |
| 4265235 | Fukunaga | May 1981 | A |
| 4280493 | Council | Jul 1981 | A |
| 4291691 | Cabal et al. | Sep 1981 | A |
| 4300550 | Gandi et al. | Nov 1981 | A |
| 4320754 | Watson et al. | Mar 1982 | A |
| 4333451 | Paluch | Jun 1982 | A |
| RE31023 | Hall, III | Sep 1982 | E |
| 4363323 | Geiss | Dec 1982 | A |
| 4403611 | Babbitt et al. | Sep 1983 | A |
| 4462397 | Suzuki | Jul 1984 | A |
| 4465067 | Koch et al. | Aug 1984 | A |
| 4485822 | O'Connor et al. | Dec 1984 | A |
| 4517404 | Hughes et al. | May 1985 | A |
| 4521038 | Cerny | Jun 1985 | A |
| 4535767 | Tiep et al. | Aug 1985 | A |
| 4559941 | Timmons et al. | Dec 1985 | A |
| 4584997 | Delong | Apr 1986 | A |
| 4602644 | DiBenedetto | Jul 1986 | A |
| 4634425 | Meer | Jan 1987 | A |
| 4648398 | Agdanowski et al. | Mar 1987 | A |
| 4660555 | Payton | Apr 1987 | A |
| 4699139 | Marshall et al. | Oct 1987 | A |
| 4778448 | Meer | Oct 1988 | A |
| 4790832 | Lopez | Dec 1988 | A |
| 4796615 | Bullock et al. | Jan 1989 | A |
| 4801093 | Brunet et al. | Jan 1989 | A |
| 4821715 | Downing | Apr 1989 | A |
| 4826510 | McCombs | May 1989 | A |
| 4829998 | Jackson | May 1989 | A |
| 4838257 | Hatch | Jun 1989 | A |
| 4893620 | Wadwha | Jan 1990 | A |
| 4949716 | Chenoweth | Aug 1990 | A |
| 4957107 | Sipin | Sep 1990 | A |
| 4989599 | Carter | Feb 1991 | A |
| 4996983 | AmRhein | Mar 1991 | A |
| 5011474 | Brennan | Apr 1991 | A |
| 5018519 | Brown | May 1991 | A |
| 5025805 | Nutter | Jun 1991 | A |
| 5027809 | Robinson | Jul 1991 | A |
| 5027812 | Shapiro et al. | Jul 1991 | A |
| 5046491 | Derrick | Sep 1991 | A |
| 5088486 | Jinotti | Feb 1992 | A |
| 5099836 | Rowland et al. | Mar 1992 | A |
| 5105807 | Kahn et al. | Apr 1992 | A |
| 5109839 | Blasdell et al. | May 1992 | A |
| 5117818 | Palfy | Jun 1992 | A |
| 5121746 | Sikora | Jun 1992 | A |
| 5140983 | Jinotti | Aug 1992 | A |
| 5222486 | Vaughn | Jun 1993 | A |
| 5243971 | Sullivan | Sep 1993 | A |
| 5269296 | Landis | Dec 1993 | A |
| 5291897 | Gastrin et al. | Mar 1994 | A |
| 5311862 | Blasdell et al. | May 1994 | A |
| 5331954 | Rex et al. | Jul 1994 | A |
| 5357948 | Eilentripp | Oct 1994 | A |
| 5400776 | Bartholomew | Mar 1995 | A |
| 5404873 | Leagre et al. | Apr 1995 | A |
| 5419317 | Blasdell et al. | May 1995 | A |
| 5429127 | Kolobow | Jul 1995 | A |
| 5437267 | Weinstein et al. | Aug 1995 | A |
| 5526806 | Sansoni | Jun 1996 | A |
| 5538000 | Rudolph | Jul 1996 | A |
| 5540221 | Kaigler et al. | Jul 1996 | A |
| 5599304 | Shaari | Feb 1997 | A |
| 5601077 | Imbert | Feb 1997 | A |
| 5603315 | Sasso, Jr. | Feb 1997 | A |
| 5605149 | Warters | Feb 1997 | A |
| 5626130 | Vincent et al. | May 1997 | A |
| 5632268 | Ellis et al. | May 1997 | A |
| 5640951 | Huddart et al. | Jun 1997 | A |
| 5664567 | Linder | Sep 1997 | A |
| 5676137 | Byrd | Oct 1997 | A |
| 5682881 | Winthrop et al. | Nov 1997 | A |
| 5683361 | Elk et al. | Nov 1997 | A |
| 5692498 | Lurie et al. | Dec 1997 | A |
| 5743258 | Sato et al. | Apr 1998 | A |
| 5752506 | Richardson | May 1998 | A |
| 5755225 | Hutson | May 1998 | A |
| 5787879 | Gibson | Aug 1998 | A |
| 5788665 | Sekins | Aug 1998 | A |
| 5803078 | Brauner | Sep 1998 | A |
| 5845633 | Psaros | Dec 1998 | A |
| 5862802 | Bird | Jan 1999 | A |
| 5873359 | Zapol et al. | Feb 1999 | A |
| 5877257 | Fetell | Mar 1999 | A |
| 5893361 | Hughes | Apr 1999 | A |
| 5901705 | Leagre | May 1999 | A |
| 5928190 | Davis | Jul 1999 | A |
| 5947119 | Reznick | Sep 1999 | A |
| 5954050 | Christopher | Sep 1999 | A |
| 5989217 | Ohki | Nov 1999 | A |
| 6012455 | Goldstein | Jan 2000 | A |
| 6058932 | Hughes | May 2000 | A |
| 6067984 | Piper | May 2000 | A |
| 6119693 | Kwok et al. | Sep 2000 | A |
| 6142147 | Head et al. | Nov 2000 | A |
| 6152132 | Psaros | Nov 2000 | A |
| 6155252 | Warters | Dec 2000 | A |
| 6228070 | Mezzoli | May 2001 | B1 |
| 6247470 | Ketchedjian | Jun 2001 | B1 |
| 6267114 | Ueno | Jul 2001 | B1 |
| 6270512 | Rittmann | Aug 2001 | B1 |
| 6279576 | Lambert | Aug 2001 | B1 |
| 6283123 | Van Meter et al. | Sep 2001 | B1 |
| 6318366 | Davenport | Nov 2001 | B1 |
| 6378520 | Davenport | Apr 2002 | B1 |
| 6394093 | Lethi | May 2002 | B1 |
| 6394142 | Woelfel et al. | May 2002 | B1 |
| 6412801 | Izuchukwu et al. | Jul 2002 | B1 |
| 6422240 | Levitsky et al. | Jul 2002 | B1 |
| 6425396 | Adriance et al. | Jul 2002 | B1 |
| 6431218 | Woelfel et al. | Aug 2002 | B1 |
| 6439230 | Gunaratnam et al. | Aug 2002 | B1 |
| 6439231 | Fukunaga et al. | Aug 2002 | B1 |
| 6446629 | Takaki et al. | Sep 2002 | B1 |
| 6463931 | Kwok et al. | Oct 2002 | B1 |
| 6505622 | Py | Jan 2003 | B2 |
| 6505624 | Campbell, Sr. | Jan 2003 | B1 |
| 6520931 | Suh | Feb 2003 | B2 |
| 6536436 | McGlothen | Mar 2003 | B1 |
| 6540718 | Wennek | Apr 2003 | B1 |
| 6543449 | Woodring et al. | Apr 2003 | B1 |
| 6561188 | Ellis | May 2003 | B1 |
| 6561193 | Noble | May 2003 | B1 |
| 6564799 | Fukunaga et al. | May 2003 | B2 |
| 6571794 | Hansen | Jun 2003 | B1 |
| 6581599 | Stenzler | Jun 2003 | B1 |
| 6584973 | Biondi et al. | Jul 2003 | B1 |
| 6604523 | Lurie | Aug 2003 | B2 |
| 6631717 | Rich | Oct 2003 | B1 |
| 6655385 | Curti et al. | Dec 2003 | B1 |
| 6659100 | O'Rourke | Dec 2003 | B2 |
| 6668828 | Figley et al. | Dec 2003 | B1 |
| 6679250 | Walker et al. | Jan 2004 | B2 |
| 6681764 | Honkonen et al. | Jan 2004 | B1 |
| 6684882 | Morine | Feb 2004 | B1 |
| 6698423 | Honkonen et al. | Mar 2004 | B1 |
| 6772761 | Rucker, Jr. | Aug 2004 | B1 |
| 6776162 | Wood | Aug 2004 | B2 |
| 6776163 | Dougill et al. | Aug 2004 | B2 |
| 6789543 | Cannon | Sep 2004 | B2 |
| 6799570 | Fisher et al. | Oct 2004 | B2 |
| 6799575 | Carter | Oct 2004 | B1 |
| 6805126 | Dutkiewicz | Oct 2004 | B2 |
| 6828577 | Zens | Dec 2004 | B2 |
| 6849049 | Starr et al. | Feb 2005 | B2 |
| 6863069 | Wood | Mar 2005 | B2 |
| 6866041 | Hardy, Jr. et al. | Mar 2005 | B2 |
| 6874500 | Fukunaga et al. | Apr 2005 | B2 |
| 6880557 | Downey | Apr 2005 | B2 |
| 6886561 | Bayron et al. | May 2005 | B2 |
| 6889688 | Wright | May 2005 | B1 |
| 6899102 | McGlothen | May 2005 | B1 |
| 6901927 | Deem et al. | Jun 2005 | B2 |
| 6915965 | Siebert | Jul 2005 | B2 |
| 6938619 | Hickle | Sep 2005 | B1 |
| 6948493 | Dunlop | Sep 2005 | B2 |
| 6983749 | Kumar | Jan 2006 | B2 |
| 6994089 | Wood | Feb 2006 | B2 |
| 6997918 | Soltesz et al. | Feb 2006 | B2 |
| 7000610 | Bennarsten et al. | Feb 2006 | B2 |
| 7007691 | Daugherty et al. | Mar 2006 | B2 |
| 7007694 | Aylsworth et al. | Mar 2006 | B2 |
| 7011094 | Rapacki et al. | Mar 2006 | B2 |
| 7013899 | Alfery et al. | Mar 2006 | B2 |
| 7017573 | Rasor et al. | Mar 2006 | B1 |
| 7032589 | Kerechanin, II et al. | Apr 2006 | B2 |
| 7036506 | McAuliffe et al. | May 2006 | B2 |
| 7051736 | Banner et al. | May 2006 | B2 |
| 7059328 | Wood | Jun 2006 | B2 |
| 7066174 | Smith et al. | Jun 2006 | B1 |
| 7096864 | Mayer et al. | Aug 2006 | B1 |
| 7100606 | Fisher et al. | Sep 2006 | B2 |
| 7114497 | Aylsworth et al. | Oct 2006 | B2 |
| 7121276 | Jagger et al. | Oct 2006 | B2 |
| 7140370 | Tresnak et al. | Nov 2006 | B2 |
| 7146976 | McKown | Dec 2006 | B2 |
| 7152604 | Hickle | Dec 2006 | B2 |
| 7165549 | Philips et al. | Jan 2007 | B2 |
| 7178521 | Burrow et al. | Feb 2007 | B2 |
| 7178524 | Noble | Feb 2007 | B2 |
| 7195018 | Goldstein | Mar 2007 | B1 |
| 7204247 | Rogerson | Apr 2007 | B1 |
| 7204249 | Richey, II et al. | Apr 2007 | B1 |
| 7204251 | Lurie | Apr 2007 | B2 |
| 7210481 | Lovell et al. | May 2007 | B1 |
| 7252088 | Nieves-Ramirez | Aug 2007 | B1 |
| 7261105 | Fukunaga et al. | Aug 2007 | B2 |
| 7273050 | Wei | Sep 2007 | B2 |
| 7275541 | Fukunaga et al. | Oct 2007 | B2 |
| 7278420 | Ganesh et al. | Oct 2007 | B2 |
| 7290543 | Stradella | Nov 2007 | B2 |
| 7318437 | Gunaratnam et al. | Jan 2008 | B2 |
| 7320447 | Lynch | Jan 2008 | B1 |
| 7328703 | Tiep | Feb 2008 | B1 |
| 7334578 | Biondi et al. | Feb 2008 | B2 |
| 7343916 | Biondo et al. | Mar 2008 | B2 |
| 7354467 | Chen et al. | Apr 2008 | B2 |
| 7383839 | Porat et al. | Jun 2008 | B2 |
| 7406966 | Wondka | Aug 2008 | B2 |
| 7418965 | Fukunaga et al. | Sep 2008 | B2 |
| 7428902 | Du et al. | Sep 2008 | B2 |
| 7434578 | Dillard et al. | Oct 2008 | B2 |
| 7445602 | Yamamori et al. | Nov 2008 | B2 |
| 7461649 | Gamard et al. | Dec 2008 | B2 |
| 7461656 | Gunaratnam et al. | Dec 2008 | B2 |
| 7478634 | Jam | Jan 2009 | B2 |
| 7481219 | Lewis et al. | Jan 2009 | B2 |
| 7481222 | Reissmann | Jan 2009 | B2 |
| 7481223 | Batistelli | Jan 2009 | B1 |
| 7503325 | Fuhrman et al. | Mar 2009 | B2 |
| 7506649 | Doshi et al. | Mar 2009 | B2 |
| 7523752 | Montgomery et al. | Apr 2009 | B2 |
| 7527053 | Devries et al. | May 2009 | B2 |
| 7533670 | Freitag et al. | May 2009 | B1 |
| 7552728 | Bonney et al. | Jun 2009 | B2 |
| 7578294 | Pierro et al. | Aug 2009 | B2 |
| 7600511 | Power et al. | Oct 2009 | B2 |
| 7617824 | Doyle | Nov 2009 | B2 |
| 7631668 | Rantalainen | Dec 2009 | B2 |
| 7655063 | Wang et al. | Feb 2010 | B2 |
| 7658189 | Davidson et al. | Feb 2010 | B2 |
| 7708016 | Zaiser et al. | May 2010 | B2 |
| 7708017 | Davidson et al. | May 2010 | B2 |
| 7717109 | Fukunaga et al. | May 2010 | B2 |
| 7717116 | Mijers | May 2010 | B2 |
| 7727194 | Nalagatla et al. | Jun 2010 | B2 |
| 7735490 | Rinaldi | Jun 2010 | B2 |
| 7735491 | Doshi et al. | Jun 2010 | B2 |
| 7740014 | Djupesland | Jun 2010 | B2 |
| 7743767 | Ging et al. | Jun 2010 | B2 |
| 7762253 | Acker et al. | Jul 2010 | B2 |
| 7775210 | Schobel et al. | Aug 2010 | B2 |
| 7779841 | Dunsmore et al. | Aug 2010 | B2 |
| 7798148 | Doshi et al. | Sep 2010 | B2 |
| 7806120 | Loomas et al. | Oct 2010 | B2 |
| 7824436 | Barbut et al. | Nov 2010 | B2 |
| 7832400 | Curti et al. | Nov 2010 | B2 |
| 7837651 | Bishop et al. | Nov 2010 | B2 |
| 7854228 | Wilson et al. | Dec 2010 | B2 |
| 7856979 | Doshi et al. | Dec 2010 | B2 |
| 7856981 | McAuley et al. | Dec 2010 | B2 |
| 7866320 | Nichols | Jan 2011 | B2 |
| 7870857 | Chuper et al. | Jan 2011 | B2 |
| 7874291 | Ging et al. | Jan 2011 | B2 |
| 7874293 | Gunaratnam et al. | Jan 2011 | B2 |
| 7900635 | Gunaratnam et al. | Mar 2011 | B2 |
| 7905232 | Olsen et al. | Mar 2011 | B2 |
| 7918224 | Dolezal et al. | Apr 2011 | B2 |
| 7918225 | Dolezal et al. | Apr 2011 | B2 |
| 7918227 | Phythyon | Apr 2011 | B1 |
| 7926484 | Dhuper et al. | Apr 2011 | B2 |
| 7942148 | Davidson et al. | May 2011 | B2 |
| 7942150 | Guney et al. | May 2011 | B2 |
| 7946288 | Flynn et al. | May 2011 | B2 |
| 7970631 | Bruggeman et al. | Jun 2011 | B2 |
| 7985254 | Tolkowsky | Jul 2011 | B2 |
| 7987847 | Wickham et al. | Aug 2011 | B2 |
| 7987852 | Doshi et al. | Aug 2011 | B2 |
| 7992561 | Baker, Jr. et al. | Aug 2011 | B2 |
| 7997266 | Frazier et al. | Aug 2011 | B2 |
| 7997267 | Ging et al. | Aug 2011 | B2 |
| 7997271 | Hickle et al. | Aug 2011 | B2 |
| 8015974 | Christopher et al. | Sep 2011 | B2 |
| 8020556 | Hayek | Sep 2011 | B2 |
| 8020558 | Christopher et al. | Sep 2011 | B2 |
| 8025054 | Dunsmore et al. | Sep 2011 | B2 |
| 8025055 | Grady | Sep 2011 | B1 |
| 8025059 | Reissmann | Sep 2011 | B2 |
| 8025635 | Eaton et al. | Sep 2011 | B2 |
| 8028697 | Grychowski et al. | Oct 2011 | B2 |
| 8042536 | Howey | Oct 2011 | B1 |
| 8042542 | Ging et al. | Oct 2011 | B2 |
| 8042546 | Gunaratnam et al. | Oct 2011 | B2 |
| 8061357 | Pierce et al. | Nov 2011 | B2 |
| 8080000 | Makower et al. | Dec 2011 | B2 |
| 8090433 | Makower et al. | Jan 2012 | B2 |
| 8113198 | Teetzel et al. | Feb 2012 | B2 |
| 8136527 | Wondka | Mar 2012 | B2 |
| 8146591 | Niklewski et al. | Apr 2012 | B2 |
| 8146592 | Voege et al. | Apr 2012 | B2 |
| 8151790 | Lurie et al. | Apr 2012 | B2 |
| 8161971 | Jaffe et al. | Apr 2012 | B2 |
| RE43398 | Honkonen et al. | May 2012 | E |
| 8171935 | Cortez, Jr. et al. | May 2012 | B2 |
| 8177805 | Alferness | May 2012 | B2 |
| 8181646 | Dhuper et al. | May 2012 | B2 |
| 8186352 | Gunaratnam et al. | May 2012 | B2 |
| 8191551 | Skovgard | Jun 2012 | B2 |
| 8196579 | Richards et al. | Jun 2012 | B2 |
| 8196582 | Ogilvie | Jun 2012 | B2 |
| 8215301 | Richards et al. | Jul 2012 | B2 |
| 8220463 | White et al. | Jul 2012 | B2 |
| 8225796 | Davenport et al. | Jul 2012 | B2 |
| 8230859 | Voege et al. | Jul 2012 | B1 |
| 8245710 | Makinson et al. | Aug 2012 | B2 |
| 8267083 | Goldstein et al. | Sep 2012 | B1 |
| 8267087 | Wruck et al. | Sep 2012 | B2 |
| 8272378 | Tutsch et al. | Sep 2012 | B2 |
| 8281557 | Doshi et al. | Oct 2012 | B2 |
| 8286636 | Gunaratnam et al. | Oct 2012 | B2 |
| 8297285 | Henry et al. | Oct 2012 | B2 |
| 8302603 | Weber | Nov 2012 | B1 |
| 8302606 | Doshi et al. | Nov 2012 | B2 |
| 8302607 | Pierce et al. | Nov 2012 | B2 |
| 8307829 | Brewer et al. | Nov 2012 | B2 |
| 8312881 | Gunaratnam et al. | Nov 2012 | B2 |
| 8312883 | Gunaratnam et al. | Nov 2012 | B2 |
| 8316851 | Wruck et al. | Nov 2012 | B2 |
| 8333194 | Lewis et al. | Dec 2012 | B2 |
| 8333199 | Landis et al. | Dec 2012 | B2 |
| 8333200 | Tero | Dec 2012 | B2 |
| 8336545 | Fink et al. | Dec 2012 | B2 |
| 8337454 | Eaton et al. | Dec 2012 | B2 |
| RE43886 | Mijers | Jan 2013 | E |
| 8342182 | Nair et al. | Jan 2013 | B2 |
| 8347881 | Tanaka et al. | Jan 2013 | B2 |
| 8347883 | Bird | Jan 2013 | B2 |
| 8348854 | Girshin | Jan 2013 | B2 |
| 8356595 | Schaeffer, Jr. et al. | Jan 2013 | B2 |
| 8371297 | Carey et al. | Feb 2013 | B2 |
| 8371302 | Ging et al. | Feb 2013 | B2 |
| 8371303 | Schaner et al. | Feb 2013 | B2 |
| 8375952 | Miller et al. | Feb 2013 | B2 |
| 8387616 | Ging et al. | Mar 2013 | B2 |
| 8402970 | Levi et al. | Mar 2013 | B2 |
| 8408204 | Lurie | Apr 2013 | B2 |
| 8408206 | Montgomery et al. | Apr 2013 | B2 |
| 8409168 | Wondka et al. | Apr 2013 | B2 |
| 8424529 | Efrati et al. | Apr 2013 | B2 |
| 8424530 | Gunaratnam et al. | Apr 2013 | B2 |
| 8439034 | Decker et al. | May 2013 | B2 |
| 8443802 | Schaeffer, Jr. et al. | May 2013 | B2 |
| 8448639 | Richards | May 2013 | B2 |
| 8469025 | Mayer et al. | Jun 2013 | B2 |
| 8469027 | Choncholas | Jun 2013 | B2 |
| 8474449 | Tanaka | Jul 2013 | B2 |
| 8475369 | Boatner et al. | Jul 2013 | B2 |
| 8486043 | Iyer et al. | Jul 2013 | B2 |
| 8522782 | Lewis et al. | Sep 2013 | B2 |
| 8534278 | Colman et al. | Sep 2013 | B2 |
| 8534286 | Pierro et al. | Sep 2013 | B2 |
| 8555877 | Djupesland | Oct 2013 | B2 |
| 8555887 | Lisogurski | Oct 2013 | B2 |
| 8561607 | Cortez, Jr. et al. | Oct 2013 | B2 |
| 8722193 | Miyai et al. | May 2014 | B2 |
| 20010037808 | Deem et al. | Nov 2001 | A1 |
| 20010047804 | Fukunaga | Dec 2001 | A1 |
| 20010054422 | Smith et al. | Dec 2001 | A1 |
| 20020017302 | Fukunaga et al. | Feb 2002 | A1 |
| 20020046755 | De Voss | Apr 2002 | A1 |
| 20020055685 | Levitsky et al. | May 2002 | A1 |
| 20020069878 | Lurie et al. | Jun 2002 | A1 |
| 20020092527 | Wood | Jul 2002 | A1 |
| 20020108610 | Christopher | Aug 2002 | A1 |
| 20020112730 | Dutkiewicz | Aug 2002 | A1 |
| 20020121278 | Hete et al. | Sep 2002 | A1 |
| 20020148464 | Hoenig | Oct 2002 | A1 |
| 20020185126 | Krebs | Dec 2002 | A1 |
| 20030075176 | Fukunaga et al. | Apr 2003 | A1 |
| 20030079750 | Berthon-Jones | May 2003 | A1 |
| 20030116163 | Wood | Jun 2003 | A1 |
| 20030131844 | Kumar et al. | Jul 2003 | A1 |
| 20030131848 | Stenzler | Jul 2003 | A1 |
| 20030154979 | Berthon-Jones | Aug 2003 | A1 |
| 20030168058 | Walker et al. | Sep 2003 | A1 |
| 20030168067 | Dougill et al. | Sep 2003 | A1 |
| 20030172929 | Muellner | Sep 2003 | A1 |
| 20030172936 | Wilkie et al. | Sep 2003 | A1 |
| 20030183231 | Pedulla et al. | Oct 2003 | A1 |
| 20030183232 | Fukunaga et al. | Oct 2003 | A1 |
| 20030209246 | Schroeder et al. | Nov 2003 | A1 |
| 20030213493 | Saad | Nov 2003 | A1 |
| 20040000306 | Stradella | Jan 2004 | A1 |
| 20040000314 | Angel | Jan 2004 | A1 |
| 20040069304 | Jam | Apr 2004 | A1 |
| 20040069309 | Kirn | Apr 2004 | A1 |
| 20040103899 | Noble | Jun 2004 | A1 |
| 20040112378 | Djupesland et al. | Jun 2004 | A1 |
| 20040112379 | Djupesland | Jun 2004 | A1 |
| 20040112380 | Djupesland | Jun 2004 | A1 |
| 20040129270 | Fishman | Jul 2004 | A1 |
| 20040134498 | Strickland et al. | Jul 2004 | A1 |
| 20040139973 | Wright | Jul 2004 | A1 |
| 20040149289 | Djupesland | Aug 2004 | A1 |
| 20040163647 | Figley et al. | Aug 2004 | A1 |
| 20040173212 | Berthon-Jones | Sep 2004 | A1 |
| 20040182397 | Wood | Sep 2004 | A1 |
| 20040194781 | Fukunaga et al. | Oct 2004 | A1 |
| 20040206354 | Fisher et al. | Oct 2004 | A1 |
| 20040216740 | Remmers et al. | Nov 2004 | A1 |
| 20040221845 | Pranger et al. | Nov 2004 | A1 |
| 20040221846 | Curti et al. | Nov 2004 | A1 |
| 20040226566 | Gunaratnam et al. | Nov 2004 | A1 |
| 20040231675 | Lyons | Nov 2004 | A1 |
| 20040244802 | Tanaka | Dec 2004 | A1 |
| 20040244804 | Olsen et al. | Dec 2004 | A1 |
| 20050005936 | Wondka | Jan 2005 | A1 |
| 20050011524 | Thomlinson et al. | Jan 2005 | A1 |
| 20050022828 | Fukunaga et al. | Feb 2005 | A1 |
| 20050028816 | Fishman et al. | Feb 2005 | A1 |
| 20050028823 | Wood | Feb 2005 | A1 |
| 20050034726 | Pittaway et al. | Feb 2005 | A1 |
| 20050039747 | Fukunaga et al. | Feb 2005 | A1 |
| 20050051163 | Deem et al. | Mar 2005 | A1 |
| 20050051176 | Riggins | Mar 2005 | A1 |
| 20050066973 | Michaels | Mar 2005 | A1 |
| 20050072430 | Djupesland | Apr 2005 | A1 |
| 20050103340 | Wondka | May 2005 | A1 |
| 20050103346 | Noble | May 2005 | A1 |
| 20050103347 | Curti et al. | May 2005 | A1 |
| 20050121033 | Starr et al. | Jun 2005 | A1 |
| 20050137715 | Phan et al. | Jun 2005 | A1 |
| 20050150501 | Opitz | Jul 2005 | A1 |
| 20050161049 | Wright | Jul 2005 | A1 |
| 20050166927 | McAuley et al. | Aug 2005 | A1 |
| 20050188990 | Fukunaga et al. | Sep 2005 | A1 |
| 20050199237 | Lurie | Sep 2005 | A1 |
| 20050205098 | Lampotang et al. | Sep 2005 | A1 |
| 20050217671 | Fisher et al. | Oct 2005 | A1 |
| 20050236000 | Wood | Oct 2005 | A1 |
| 20050252515 | Wood | Nov 2005 | A1 |
| 20050257794 | Aylsworth et al. | Nov 2005 | A1 |
| 20060011198 | Matarasso | Jan 2006 | A1 |
| 20060042631 | Martin et al. | Mar 2006 | A1 |
| 20060042632 | Bishop et al. | Mar 2006 | A1 |
| 20060042634 | Nalagatla et al. | Mar 2006 | A1 |
| 20060042636 | Nalagatla et al. | Mar 2006 | A1 |
| 20060042637 | Martin et al. | Mar 2006 | A1 |
| 20060042638 | Niklewski et al. | Mar 2006 | A1 |
| 20060060204 | Fuentes | Mar 2006 | A1 |
| 20060081257 | Krogh et al. | Apr 2006 | A1 |
| 20060107957 | Djupesland | May 2006 | A1 |
| 20060130840 | Porat et al. | Jun 2006 | A1 |
| 20060144401 | Boelt | Jul 2006 | A1 |
| 20060150979 | Doshi et al. | Jul 2006 | A1 |
| 20060150982 | Wood | Jul 2006 | A1 |
| 20060169281 | Aylsworth et al. | Aug 2006 | A1 |
| 20060174886 | Curti et al. | Aug 2006 | A1 |
| 20060174888 | Aylsworth et al. | Aug 2006 | A1 |
| 20060196502 | Pilcher et al. | Sep 2006 | A1 |
| 20060201512 | Garrett et al. | Sep 2006 | A1 |
| 20060207596 | Lane | Sep 2006 | A1 |
| 20060243278 | Hamilton et al. | Nov 2006 | A1 |
| 20060272645 | Ging et al. | Dec 2006 | A1 |
| 20070062538 | Foggia et al. | Mar 2007 | A1 |
| 20070062539 | Gunaratnam et al. | Mar 2007 | A1 |
| 20070068521 | Wang et al. | Mar 2007 | A1 |
| 20070107728 | Ricciardelli et al. | May 2007 | A1 |
| 20070107737 | Landis et al. | May 2007 | A1 |
| 20070113847 | Acker et al. | May 2007 | A1 |
| 20070113848 | Acker et al. | May 2007 | A1 |
| 20070113850 | Acker et al. | May 2007 | A1 |
| 20070113856 | Acker et al. | May 2007 | A1 |
| 20070119451 | Wang et al. | May 2007 | A1 |
| 20070137644 | Dhuper et al. | Jun 2007 | A1 |
| 20070163588 | Hebrank et al. | Jul 2007 | A1 |
| 20070175473 | Lewis et al. | Aug 2007 | A1 |
| 20070186928 | Be'eri | Aug 2007 | A1 |
| 20070186930 | Davidson et al. | Aug 2007 | A1 |
| 20070193580 | Feldhahn et al. | Aug 2007 | A1 |
| 20070199566 | Be'eri | Aug 2007 | A1 |
| 20070199568 | Diekens et al. | Aug 2007 | A1 |
| 20070233012 | Lerrick et al. | Oct 2007 | A1 |
| 20070256690 | Faram | Nov 2007 | A1 |
| 20070267025 | Lyons et al. | Nov 2007 | A1 |
| 20070277823 | Al-Ali et al. | Dec 2007 | A1 |
| 20070277832 | Doshi et al. | Dec 2007 | A1 |
| 20070283957 | Schobel et al. | Dec 2007 | A1 |
| 20080041373 | Doshi et al. | Feb 2008 | A1 |
| 20080041393 | Bracken | Feb 2008 | A1 |
| 20080051674 | Davenport et al. | Feb 2008 | A1 |
| 20080053458 | De Silva et al. | Mar 2008 | A1 |
| 20080060649 | Veliss et al. | Mar 2008 | A1 |
| 20080078388 | Vandine | Apr 2008 | A1 |
| 20080078393 | Acker et al. | Apr 2008 | A1 |
| 20080092891 | Cewers | Apr 2008 | A1 |
| 20080092906 | Gunaratnam et al. | Apr 2008 | A1 |
| 20080110451 | Dunsmore et al. | May 2008 | A1 |
| 20080110455 | Dunsmore et al. | May 2008 | A1 |
| 20080115787 | Ingenito | May 2008 | A1 |
| 20080121230 | Cortez et al. | May 2008 | A1 |
| 20080142003 | Depel | Jun 2008 | A1 |
| 20080142012 | Farnsworth et al. | Jun 2008 | A1 |
| 20080142018 | Doshi et al. | Jun 2008 | A1 |
| 20080142019 | Lewis et al. | Jun 2008 | A1 |
| 20080167603 | Stenzler et al. | Jul 2008 | A1 |
| 20080178879 | Roberts et al. | Jul 2008 | A1 |
| 20080190436 | Jaffe et al. | Aug 2008 | A1 |
| 20080196728 | Ho | Aug 2008 | A1 |
| 20080216838 | Wondka | Sep 2008 | A1 |
| 20080251079 | Richey | Oct 2008 | A1 |
| 20080276937 | Davidson et al. | Nov 2008 | A1 |
| 20080276941 | Doty et al. | Nov 2008 | A1 |
| 20090025723 | Schobel et al. | Jan 2009 | A1 |
| 20090044808 | Guney et al. | Feb 2009 | A1 |
| 20090056717 | Richards et al. | Mar 2009 | A1 |
| 20090065001 | Fishman | Mar 2009 | A1 |
| 20090071481 | Fishman | Mar 2009 | A1 |
| 20090101147 | Landis et al. | Apr 2009 | A1 |
| 20090133697 | Kwok et al. | May 2009 | A1 |
| 20090145441 | Doshi et al. | Jun 2009 | A1 |
| 20090188493 | Doshi et al. | Jul 2009 | A1 |
| 20090194109 | Doshi et al. | Aug 2009 | A1 |
| 20090197240 | Fishman et al. | Aug 2009 | A1 |
| 20090205650 | Tanaka et al. | Aug 2009 | A1 |
| 20090217929 | Kwok et al. | Sep 2009 | A1 |
| 20090241965 | Sather et al. | Oct 2009 | A1 |
| 20090248057 | Kotler | Oct 2009 | A1 |
| 20090250066 | Daly | Oct 2009 | A1 |
| 20090260625 | Wondka | Oct 2009 | A1 |
| 20090266365 | Oberle | Oct 2009 | A1 |
| 20090306529 | Curti et al. | Dec 2009 | A1 |
| 20090308398 | Ferdinand et al. | Dec 2009 | A1 |
| 20100000534 | Kooij et al. | Jan 2010 | A1 |
| 20100043801 | Halling et al. | Feb 2010 | A1 |
| 20100065053 | Haveri | Mar 2010 | A1 |
| 20100069770 | Girshin et al. | Mar 2010 | A1 |
| 20100069820 | Zotz | Mar 2010 | A1 |
| 20100070050 | Mathis et al. | Mar 2010 | A1 |
| 20100071693 | Allum et al. | Mar 2010 | A1 |
| 20100168511 | Muni | Jul 2010 | A1 |
| 20100192957 | Hobson et al. | Aug 2010 | A1 |
| 20100212663 | Vedrine et al. | Aug 2010 | A1 |
| 20100229865 | Boussignac | Sep 2010 | A1 |
| 20100252042 | Kapust et al. | Oct 2010 | A1 |
| 20100326441 | Zucker et al. | Dec 2010 | A1 |
| 20100326447 | Loomas et al. | Dec 2010 | A1 |
| 20110005528 | Doshi et al. | Jan 2011 | A1 |
| 20110005530 | Doshi et al. | Jan 2011 | A1 |
| 20110009763 | Levitsky et al. | Jan 2011 | A1 |
| 20110011397 | Ziv et al. | Jan 2011 | A1 |
| 20110011400 | Gentner et al. | Jan 2011 | A1 |
| 20110017207 | Hendricksen et al. | Jan 2011 | A1 |
| 20110023891 | Blach et al. | Feb 2011 | A1 |
| 20110030685 | Wilkinson et al. | Feb 2011 | A1 |
| 20110040158 | Katz et al. | Feb 2011 | A1 |
| 20110041855 | Gunaratnam et al. | Feb 2011 | A1 |
| 20110067704 | Kooij et al. | Mar 2011 | A1 |
| 20110067708 | Doshi et al. | Mar 2011 | A1 |
| 20110073110 | Kenyon et al. | Mar 2011 | A1 |
| 20110073116 | Genger et al. | Mar 2011 | A1 |
| 20110094518 | Cipollone et al. | Apr 2011 | A1 |
| 20110100369 | Zhang et al. | May 2011 | A1 |
| 20110108041 | Sather et al. | May 2011 | A1 |
| 20110114098 | McAuley et al. | May 2011 | A1 |
| 20110125052 | Davenport et al. | May 2011 | A1 |
| 20110146674 | Roschak | Jun 2011 | A1 |
| 20110209709 | Davidson et al. | Sep 2011 | A1 |
| 20110245579 | Bruggeman et al. | Oct 2011 | A1 |
| 20110271962 | White et al. | Nov 2011 | A1 |
| 20110290256 | Sather et al. | Dec 2011 | A1 |
| 20120080037 | Guyuron et al. | Apr 2012 | A1 |
| 20120111332 | Gusky et al. | May 2012 | A1 |
| 20120118286 | Barodka | May 2012 | A1 |
| 20120125332 | Niland et al. | May 2012 | A1 |
| 20120157794 | Goodwin et al. | Jun 2012 | A1 |
| 20120167894 | O'Leary | Jul 2012 | A1 |
| 20120192869 | Hayek | Aug 2012 | A1 |
| 20120192870 | Dugan et al. | Aug 2012 | A1 |
| 20120209096 | Jaffe et al. | Aug 2012 | A1 |
| 20120247480 | Varga | Oct 2012 | A1 |
| 20120285463 | Dillingham et al. | Nov 2012 | A1 |
| 20120285470 | Sather et al. | Nov 2012 | A9 |
| 20120325205 | Allum et al. | Dec 2012 | A1 |
| 20120325206 | Allum et al. | Dec 2012 | A1 |
| 20120325218 | Brambilla et al. | Dec 2012 | A1 |
| 20130008447 | Gunaratnam et al. | Jan 2013 | A1 |
| 20130014754 | Guerra et al. | Jan 2013 | A1 |
| 20130019864 | Wondka | Jan 2013 | A1 |
| 20130092159 | Ulrichskotter et al. | Apr 2013 | A1 |
| 20130092165 | Wondka | Apr 2013 | A1 |
| 20130092173 | Alexander et al. | Apr 2013 | A1 |
| 20130104888 | Landis et al. | May 2013 | A1 |
| 20130104901 | Landis et al. | May 2013 | A1 |
| 20130158475 | Xia et al. | Jun 2013 | A1 |
| 20130184602 | Brambilla | Jul 2013 | A1 |
| 20130190643 | Brambilla | Jul 2013 | A1 |
| 20130211275 | Curti | Aug 2013 | A1 |
| 20130263854 | Taylor et al. | Oct 2013 | A1 |
| 20130312752 | Kapust et al. | Nov 2013 | A2 |
| 20130323491 | Takahashi et al. | Dec 2013 | A1 |
| 20130327334 | Pierro et al. | Dec 2013 | A1 |
| Number | Date | Country |
|---|---|---|
| WO-2012006415 | Jan 2012 | WO |
| WO-2012106373 | Aug 2012 | WO |
| Entry |
|---|
| Non-Final Office Action in U.S. Appl. No. 14/096,910, dated Apr. 25, 2014, 45 pages. |
| PCT International Search Report and Written Opinion in PCT/US2013/073082, mailed Apr. 3, 2014, 17 pages. |
| PCT International Search Report and Written Opinion in PCT/US2013/073142, mailed Apr. 3, 2014, 17 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20140150789 A1 | Jun 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61733134 | Dec 2012 | US | |
| 61784238 | Mar 2013 | US | |
| 61856367 | Jul 2013 | US |
